WO2002044730A1 - Identification rapide de conditions, de composes ou de compositions qui inhibent, previennent, induisent, modifient ou inversent des transitions d'etat physique - Google Patents

Identification rapide de conditions, de composes ou de compositions qui inhibent, previennent, induisent, modifient ou inversent des transitions d'etat physique Download PDF

Info

Publication number
WO2002044730A1
WO2002044730A1 PCT/US2001/044818 US0144818W WO0244730A1 WO 2002044730 A1 WO2002044730 A1 WO 2002044730A1 US 0144818 W US0144818 W US 0144818W WO 0244730 A1 WO0244730 A1 WO 0244730A1
Authority
WO
WIPO (PCT)
Prior art keywords
samples
disease
array
causing substance
medium
Prior art date
Application number
PCT/US2001/044818
Other languages
English (en)
Inventor
Douglas Levinson
Original Assignee
Transform Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals, Inc. filed Critical Transform Pharmaceuticals, Inc.
Priority to AU2002217953A priority Critical patent/AU2002217953A1/en
Priority to US10/103,983 priority patent/US20050118637A9/en
Priority to US10/142,812 priority patent/US20050089923A9/en
Publication of WO2002044730A1 publication Critical patent/WO2002044730A1/fr
Priority to US10/235,553 priority patent/US20050095696A9/en
Priority to US10/235,922 priority patent/US6977723B2/en
Priority to US10/235,922 priority patent/US20040252299A9/en
Priority to US11/051,517 priority patent/US7061605B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers

Definitions

  • the invention is directed to methods and systems for high through-put sample screening for optimization of conditions and discovery of new compounds and compositions.
  • the invention is directed to methods and systems for high- throughput, rapid screening of large numbers of samples for identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state, particularly, where the physical-state transition relates to a disease process.
  • Formation of disease-causing substances can occur by many different mechanisms. h general, a physical-state transition is involved. For example, bio-precipitation and bio- crystallization processes, such as mineralization (crystallization and buildup of minerals) and calcification (crystallization of calcium salts). Disease-causing substances can also form by a physical-state shift from one solid to a more unfavorable solid, for example, a polymorphic shift. Crystallization is a physical-state change that results in the formation of a crystalline substance. The process of crystallization is one of ordering. During this process, randomly organized molecules in a solution, an amorphous substance, a melt, or the gas phase take up specific, ordered positions in a crystal matrix.
  • crystallization from solution, for example, crystallization in bodily fluids.
  • precipitation is usually reserved for formation of amorphous substances that have no symmetry or ordering and cannot be defined by habits or as polymorphs.
  • Bio- precipitation processes can result in organic deposits, such as plaques, fats, and other undesirable amorphous-substance buildup in the body.
  • Both crystallization and precipitation result from the inability of a solution (e.g., body fluid) to fully dissolve the substance and can be induced by changing the state of the system in some way.
  • Common parameters that can promote or discourage precipitation or crystallization include: pH; temperature; concentration; and the presence or absence of inhibitors or impurities.
  • a process akin to crystallization that is typically limited to formation of substances displaying local order is that of deposition or polymerization of proteins and other molecules resulting in deposits and other aggregates.
  • Such aggregates result in disease state such as those seen in sickle cell disease with polymerization of hemoglobin that is rate limited by a nucleation step, a stochastic process, in manner similar to crystallization and precipitation.
  • Additional examples include Huntington's chorea (caused by aggregates including the protein huntingtin), Parkinson's disease, and many other disorders.
  • Important processes in crystallization and precipitation are nucleation, growth kinetics, interfacial phenomena, agglomeration, and breakage.
  • Growth is the enlargement of particles caused by deposition of solid material on an existing surface.
  • Agglomeration is the formation of larger particles through two or more particles (e.g., crystals) sticking together.
  • the thermodynamic driving force for both nucleation and growth is supersaturation. which is defined as the deviation from thermodynamic equilibrium.
  • an adduct molecule can be incorporated into the matrix, adsorbed on the surface, or trapped within the particle or crystal.
  • inclusions such as hydrates (water molecule incorporated in the matrix) and solvates (solvent trapped within a matrix).
  • inclusions may dissolve more or less readily in bodily fluids or have different mechanical properties or strength than the corresponding non-inclusion compounds.
  • the same compound can crystallize in different external shapes depending on, amongst others, the composition of the crystallizing medium. These crystal- face shapes are described as the crystal habit. Such information is important because the crystal habit has a large influence on the crystal's surface-to-volume ratio. Although crystal habits have the same internal structure and thus have identical single crystal- and powder-diffraction patterns, they can still exhibit different pharmaceutical properties (Haleblian 1975, J. Pharm. Sci., 64:1269). Crystal size and shape of disease-causing substances have a great effect on the clinical aspects of a disease, such as irritation and inflammation. Thus discovering conditions or pharmaceuticals that affect crystal habit are needed.
  • the same compound can crystallize as more than one distinct crystalline species (i.e., having a different internal structure and physical properties) or shift from one crystalline species to another.
  • This phenomena is known as polymorphism and the distinct species known as polymorphs.
  • Polymorphs can exhibit different optical properties, melting points, different solubility, different chemical reactivities, different dissolution rates, and different bioavailabilities. Factors that affect polymorphism of foreign substances in the body are of clinical importance. For example, one polymorph may be more readily removed from the body - e.g., easier to dissolve in body fluids- than another. Thus, conditions, compounds, or compositions that prevent shift to an unfavorable polymorph or promote shift to a more favorable polymorph are desirable.
  • particles can form from solution in different sizes and size distributions. In general, smaller particles are more easily eliminated from the body and have higher surface- to-volume ratio that allows easier dissolution in bodily fluids. Thus, compounds or compositions that promote small crystal size can be of clinical importance in treating or preventing diseases caused by solid deposits in the body.
  • Disease-processes can also be induced by pathogenic degradations of substances in the body, for example, loss of bone mass caused by bone resoiption or osteoporosis.
  • pathogenic degradations of substances in the body for example, loss of bone mass caused by bone resoiption or osteoporosis.
  • therapeutic compositions, compounds, or conditions that slow or reverse such processes are greatly needed.
  • Another instance of unfavorable biocrystallization or bioprecipitation concerns physiologically low-solubility pharmaceuticals or pharmaceuticals that complex with tissue or other bodily substances.
  • Compounds that prevent or inhibit such crystallization or precipitation may have clinical applications, such as coadministration with the problematic pharmaceutical.
  • Calcium pyrophosphate dihydrate (CPPD) crystals maybe deposited in joint spaces. Here they cause inflamation with pain and swelling and limitation of motion of the involved joint. These CPPD crystals are rod or rhomboid shapes 2-20 micrometers long, they are weakly birefringement crystals. Any joint can be involved but the most common are the knee, wrist and metacarpophalangeal joint. Acute attacks of pseudogout often occur in the knees and are incapacitating for days or weeks. The disease is most frequent in the elderly of both genders. The clinical presentation may be confused with gout hence its common name "pseudogout syndrome". Unfortunately, no treatment is available to dissolve the crystal deposits.
  • Apatite crystal deposition is a common factor in bursitis and periarthritis. Most common areas of involvement are shoulders, hips, knees and digits. An extremely destructive arthritis may occur at the shoulder, "Milwaukee shoulder,” or at hips and knees in elderly people. Other types of calcium phosphates such as octacalcium phosphate can be seen along with the apatite crystals.
  • apatite crystals that form in this type of disease are very small and can be seen only by electron microscope, however, clumps of these crystals often form and appear as 2-25 MM shing (but not generally birefringent), globules in the light microscope and when seen are strongly suggestive of the diagnosis. Radiographs may show soft tissue calcifications with or without bone erosions. Definitive diagnosis of this type of crystal deposition disease can only be made by electron microscopy with electron probe elemental analysis, x-ray diffraction or infrared spectroscopy.
  • Apatite deposition can also be associated with scleroderma and other connective tissue diseases, repeated depot corticosteroid injections, high dose vitamin D therapy and injury to the central nervous system, however, in most cases the cause of soft tissue apatide deposition is not known.
  • the acute arthritis or periarthritis can be treated with VSAJDS or colchicine but no agent capable of preventing this potentially destructive type of phase transition is known.
  • Oxalates may deposit in vessels walls and can mimic vasculitis.
  • Monosodium urate crystals may deposit in joints and other connective tissue causing gout. Gout is the most common and prototypic of the crystal deposition disease.
  • Monosodium urate crystals are rods or needles up to 15 to 20 micrometers in length and are brightly birefringent with negative elongation when viewed with compensated polarized light.
  • Chronic or recurrent acute gout can be polyarticular and can mimic rheumatoid arthritis. Crystals are often present in joint fluid even between attacks and may contribute to low-grade inflammation and joint damage. The presence of uric acid crystals in the kidneys can cause renal failure. Treatment options for gout are also limited with the effective treatment comprising administration of colchicine for acute gout notwithstanding its side effects of nausea, vomiting and diarrhea. A more modern treatment is the use of non-steroidal anti- inflammatory drugs, and in particular the agent indomethicin.
  • Aspirin and aspirin containing products are preferably avoided during acute gout and xanthine oxidase inhibitors such as allopurinol administered to control high levels of uric acid. It should be noted that these are palliative treatments. Listed below are the differential diagnostic features for some of the crystal- associated arthropathies. (From Cecil Textbook of Medicine, Eds. Goldman L. & Bennett J.C., 21 st Edition (2000), W.B. Saunders Co., Philadelphia)
  • Nephrolithiasis is a common disorder defined as the development of stones within the urinary tract. It is a major cause of morbidity in the United States and elsewhere. Approximately 12% of the population of the United States will have a kidney stone at some time in their lives. The economic impact is more than $2 billion dollars per year. Kidney stones are two to three times more common in men than in women and in the U.S. are most common in the southeast.
  • Formation of kidney stones results from (1) initial formation of crystals (nucleation), (2) reduced effects of normal urinary constituents that inhibit crystal growth and aggregation; (3) the presence of substances promoting crystal growth and aggregation; and (4) the processes that determine crystal attachment to the surface of renal papillary epithelial cells.
  • ESWL extracorporeal shock wave lithotripsy.
  • the composition of kidney stones is variable. However, about three-fourths of all stones are composed of calcium oxalate: 35% of stones are pure calcium oxalate (calcium oxalate monohydrate or calcium oxalate dihydrate or both): 40% are calcium oxalate with hydroxyapatite or carbonate apatite; and 1% are calcium oxalate with uric acid.
  • the non-calcium-containing crystal stones are struvite (magnesium ammonium phosphate) and comprise 8% of all stones. In addition, eight percent of all stones are composed of uric acid and 2% of cystine. h rare cases stones maybe composed of acid ammonium urate or xanthine or insoluble drugs.
  • Bone is a complex organ system whose functions include support, locomotion encasement of hematopoietic or central nervous system tissue and reservoir for calcium, phosphate and magnesium.
  • the cortices of all bone and the interior of certain bones have a continuous structure termed cortical or lamellar bone.
  • Lamellar bone is characterized by a highly organized extracellular matrix of mineral and parallel bundles of type I collagen, hi some pathologic states bone may assume a less organized or so called "woven" architecture.
  • Bone consists of an organic component called "osteoid” that is able to accumulate a mineral physical-state consisting of amorphous and crystalline states of hydroxy apatite Ca 5 (OH)(PO 4 ) 3 .
  • Osteoid is primarily (90-95%) composed of bundles of type I collagen which consists of a long triple helix of two alpha] chains and one alpha j chain.
  • the collagen of cartilage matrix is type ⁇ and is a trimer of three alpha j chains.
  • Elastic tissue consists of type UJ collagen.
  • the osteoblast is a cuboidal bone matrix-synthesizing cell. It lines the surface at which bone formation takes place.
  • the plasma membrane of the osteoblast is highly enriched with a bone specific isoform of the alkaline phosphatase enzyme. This enzyme promotes bone mineralization by catalyzing, in supersaturated extracellular fluid of bone, the hydrolysis of pyrophosphate and other inhibitors of calcium-phosphate crystallization.
  • the osteoclast is the main bone-resorbing cell. It is a highly mobile multinucleate giant cell with several specialized features for bone.
  • the osteoclast has organells that mediate cell attachment to bone surface (podosomes), a ruffled border at the bone face for ion transport, many enzymes that can function in bone resorption and a high concentration of carbonic anhydrase JJ which helps acidify the extracellular pocket between the osteoclast ruffled border and the skeletal resorption surface.
  • the regulation of bone formation and removal is complex and involves both systemic and local regulation.
  • the systemic regulators include parathyroid hormone (PTH), calcitonin and calcitriol. -n addition there is a highly complex network of local controls. Only a few of these so called osteoclast-activating factors have been identified.
  • interleukin-1 and lymphotoxin/tumor necrosis factor-beta are stimulators of bone resorption that seem to be released locally by some tumors in bone.
  • Parathyroid hormone- related protein (PTH-RP) is a local mediator which may be responsible for the humoral h percalcemic of malignancy.
  • the activators of bone resorption are poorly understood but insulin-like growth factor type 1 and transforming growth factor-beta are present in osteoblasts and osteocytes and may play a role.
  • Osteoporosis is the most common type of metabolic bone disease and is characterized by a reduction in bone mineral density and bone matrix. Osteoporosis affects 20 million Americans and leads to approximately 1.3 million fractures in the U.S. each year. The disease affects women more than men and it is estimated that women lose about 50% of their trabecular bone and 30% of their cortical bone over the course of their lifetime. By extreme old age, one third of all women and one sixth of all men will have a hip fracture. The annual cost due to osteoporosis has been estimated to be nearly 14 billion dollars in the U.S. alone. Peak bone density is reached in young adulthood and remains stable for many years, but then declines with age.
  • the rate of bone density loss in women increases several fold after menses cease. During the first 5 to 10 years after menopause, a woman may lose 10% to 15% of her cortical bone and 25%-30% of her trabecular bone mass. Bone density loss rate in men is less, but also increases sharply as age increases. The loss of bone density caused by osteoporosis results in fractures of the hip, pelvis, wrist, proximal humerus, proximal tibia and vertebral bodies. The disease may be asymptomatic until it results in a fracture, often a vertebral compression fracture, or a fracture of the wrist, hip or pelvis with accompanying pain and disability.
  • osteoporosis causes many, including decreasing levels of estrogens in women and androgens in men. hi addition, many other disorders may lead to osteoporosis, such as hyperprolactinemia, anorexia nervosa, hyperthyroidism, hypercortisolism, and growth hormone deficiency. In addition, many drugs can cause bone loss, such as heparin, ethanol, glucocorticoids and some anti-convulsants.
  • Such an agent could be used to promote bone growth where it is desired, such as at fracture sites and in the regions surrounding bone implants.
  • Such an agent could act as a nucleation site or otherwise act to induce bone formation and/or prevent bone loss.
  • the methods of the present invention can be used to screen large numbers of agents to determine if they are able to act in this way in the huge variety of circumstances in which this would be desirable.
  • Ectopic mineralization is a consequence of a significant number and variety of disorders. These are illnesses that alter levels of calcium or phosphate or in some other manner cause the abnormal precipitation of amorphous calcium phosphate or hydroxyapatite. hi some of these disorders, true bone tissue is formed in abnormal locations. The patho genesis of this ectopic mineralization is generally due to one of three mechanisms.
  • a supranormal "calcium-phosphate solubility product" in extracellular fluid can cause "metastatic” calcification.
  • Calcium and inorganic phosphate are normally present in serum or extracellular fluid at concentrations that form a “metastable” solution. Their levels are too low for spontaneous precipitation but sufficiently great to cause hydroxyapatite Ca 10 (PO 4 ) 6 (OH) 2 formation once crystal nucleation has begun.
  • This process is controlled by the presence of a variety of inhibitors of mineralization such as inorganic pyrophosphate which helps prevent inappropriate calcification in healthy tissues.
  • metastatic calcification is a risk if significant hypercalcemia or hyperphosphatemia or both occur for any reason.
  • Direct precipitation of mineral occurs when the critical calcium- phosphate solubility product in extracellular fluid is exceeded. When this parameter (mg/dl x mg dl) exceeds 75, mineral precipitation will occur.
  • the critical value for renal calcification may be lower and may vary with age.
  • the mineral that is deposited in metastatic calcification may be amorphous calcium phosphate but hydroxyapatite is formed soon after. The pattern of deposition varies somewhat depending on whether calcium or phosphate is in excess but occurs irrespective of the specific underlying condition or mechanism causing the disturbed mineral homeostasis. In addition there is a predilection for precipitation into certain tissues.
  • Hypercalcemia is often associated with mineral deposits in the kidney, lungs and Malawis of the stomach, h addition, the media of large arteries, elastic tissue of the endocardium (especially the left atrium), conjunctive and peri-articular soft tissues are often affected, hi the kidneys, hypercalciuria may cause calcium phosphate casts to form within the tubule lumen or calculi to develop in the calyces or pelvis. Calcium phosphate may precipitate in peritubular tissues. In the lungs, calcification affects the alveolar walls and the pulmonary venous system. Metastatic calcification caused by hypercalcemia is often caused by the Milk Alkali Syndrome, hypervitamosis D, Sarcoidosis, and hyperparathyroidism.
  • Hype ⁇ hosphatemia may occur with idiopathic hype ⁇ arathyroidism or pseudohypoparthyroidism and with the massive cell lysis (release of cellular phosphate) that can follow chemotherapy for leukemia.
  • Hype ⁇ hosphatemia produces ectopic calcification in locations different from that caused by hypercalcemia. For example, hype ⁇ hosphatemia is more likely to result in calcification of periarticular subcutaneous tissues and in certain parts of the CNS such as the cerebral basal ganglion.
  • a third type of tissue calcification may also occur despite a normal serum calcium- phosphate solubility product. This process is called dystrophic calcification and is precipitated by the release from injured tissue of, as yet unknown, material that has nucleating properties.
  • dystrophic calcification is precipitated by the release from injured tissue of, as yet unknown, material that has nucleating properties.
  • One example of the phenomenon is the calcification of the lesion of tuberculosis, which will occur with normal levels of calcium and phosphate.
  • calcinosis An important type of this "injury induced” or dystrophic calcification commonly occurs in or under the skin in connective tissue disorder and is called “calcinosis.” This occurs commonly in Dermatomyositis, Scleroderma and Systemic Lupus Erythematosis. Calcinosis may also occur when tissue is injured by metastasis or trauma. The lesions of calcinosis are small or medium sized hard nodules that can cause muscle atrophy, and contractions, and may produce significant disability. h addition to diseases in which calcium phosphate is deposited in tissue because of a high solubility product or because of release of materials that have nucleating properties, it is also possible for "true" bone to form ectopicly.
  • the bone formed in these diseases is lamellar, actively remodeled by osteoblasts and osteoclasts, and like true bone, has Haversian systems and sometimes contains marrow.
  • the injured or diseased tissue contains all the necessary precursor cells and inductive signals to form bone. This phenomenon may occur following an injury or trauma or may occur as a separate heritable entity called Fibrodysplasia Ossificans Progressiva.
  • Dental plaque is the accumulation of bacteria and organic matter on teeth.
  • Dental calculus is the formation of calcium phosphate crystals around and in this organic matter. Therefore, formation of the hard deposits of dental calculus involves the mineralization of the plaque deposits.
  • Dental calculus is a distinct oral detriment because it is especially difficult to remove with dental floss and serves as a localized physical irritant to the gingival tissue. Furthermore, dental calculus contains endotoxins and other microbial constituents which are etiological factors in the initiation of gingivitis. Perhaps of greatest importance is that dental calculus has greater porosity as compared to the normal tooth surface and this allows the bacterial accumulation that enables dental plaque to occur at a faster rate. (See Beiswanger et al, 1989, J! Clin. Dent. 1:55-58).
  • Gallstones are concretions that form in the biliary tree, mostly in the gallbladder when conditions favor the precipitation, as solid crystals, of certain biliary solutes such as cholesterol and calcium that are normally held in solution. These crystals may grow and aggregate within the mucus layer lining the gall bladder.
  • Gallstones are formed when bile becomes supersaturated with cholesterol or calcium.
  • the conditions must allow the solute to nucleate from solution and precipitate as solid crystals of cholesterol or bilirubin.
  • the third step in the process occurs when the crystals aggregate and fuse to form stones. This aggregation occurs in a mucus gel along the wall of the gallbladder, h addition, gallstone formation may be associated with impaired gallbladder motility resulting in impaired contractile response of the gallbladder muscle to cholecystokinin. This is thought to be secondary to cholesterol accumulation in the gallbladder muscle itself.
  • Cholesterol gallstones are yellow-brown and range in size from a few millimeters to 2-3 cm. More than 50%, and often over 90%, of their dry weight consists of crystalline cholesterol monohydrate. Small but variable amounts of other components such as mucin glycoproteins and calcium bilirubinate may also be present. Cholesterol gallstones form when the amount of cholesterol secreted into bile exceed the amount that can be held in stable micellar solution by the concentrations of bile salts and lecithin present. The cholesterol saturation index indicates the degree of cholesterol saturation of the bile. An index value greater than one indicates supersaturation.
  • vesicles When bile is unsaturated, newly secreted vesicles containing cholesterol and lecithin are dissolved completely by bile salts as bile is concentrated in the gallbladder. However, if the bile is supersaturated, vesicles fail to dissolve completely and instead fuse to form large, cholesterol-rich multilamellar liquid crystals from which excess cholesterol may precipitate as plate-like cholesterol monohydrate crystals.
  • Biliary cholesterol supersaturation can be caused by a primary increase in biliary secretion of cholesterol or by a deficiency of bile salts.
  • Estrogen causes an increase in the rate of biliary cholesterol secretion into bile. This may account for the two-fold increase risk of cholesterol gallstones in women during their childbearing years.
  • Obesity is also associated with an increased biliary cholesterol secretion.
  • some hypocholesterolemic drugs such as the fibric acid derivatives clofibrate and gemfibrizol directly stimulate secretion of cholesterol into bile and are associated with increased risk of cholesterol gallstones.
  • Approximately 20% of U.S. gallstones are pigment gallstones.
  • These stones are composed of calcium salts of organic and inorganic anions, especially bilirubin. Ionized calcium is present in bile at concentrations similar to those of plasma. Unconjugated bilirubin has a low solubility product with calcium and its presence in bile even in small amounts favors precipitation of calcium bilirubinate.
  • Black pigment gallstones are hard, dense, brittle concretions composed of calcium bilirubinate along with inorganic calcium salts of carbonate and phosphate.
  • Brown pigment gallstones have a soft clay-like consistency. They contain calcium bilirubinate plus a substantial proportion of calcium soaps of fatty acids. Brown pigment stones occur in chronically infected bile in areas of stasis, where bacterial cleavage of phospholipid and conjugated bilirubin releases unconjugated bilirubins and fatty acids.
  • Bile supersaturation is only one of a variety of abnormalities which contribute to the formation of both cholesterol and pigment gallstones. Precipitation of crystals from supersaturated bile requires the formation of an initial solid nidus (nucleation) with subsequent deposition of solute on the surface leading to crystal growth. Some individuals have very slow nucleation and do not develop gallstones despite secreting supersaturated bile. Nucleation and growth of cholesterol crystals is much more rapid in bile of gallstone patients than in gallstone-free controls for equal degrees of cholesterol supersaturation. The nucleation and growth of cholesterol crystals may be accelerated or retarded by the presence of certain proteins in bile.
  • Nascent cholesterol crystals precipitating from vesicles or mixed micelles are trapped in a mucin gel lining of the gallbladder. Over time these crystals fuse to form macroscopic stones. Mucus secretion is stimulated by prostaglandins and in animal models the prevention of excessive mucin secretion by cycloxygenase inhibitors can prevent cholesterol gallstone formation. Thus the formation of gallstones is a major medical problem associated with significant morbidity and mortality and expense.
  • Sickle cell disease is an inherited disorder caused by the abnormal properties of red blood cells containing a form of mutant sickle cell hemoglobin (HbS).
  • HbS sickle cell hemoglobin
  • Normal hemoglobin is a complex protein formed from two alpha and two beta globin polypeptide chains.
  • This mutation is the substitution of a T for an A in the sixth codon of the beta-globin gene.
  • This single nucleotide substitution causes a substitution of the amino acid Glu for Val on the sixth position of the polypeptide chain that forms beta-globin.
  • Sickle disease can cause serious organ damage due to the reduction of blood flow in small vessels.
  • the growth and development of a child with sickle disease may be retarded and specific damage may occur to the CNS, lungs, kidney, eyes, heart and skin.
  • a common and extremely serious condition called osteonecrosis may occur because of the reduction of blood flow to the bones, resulting in painful bone infarctions.
  • the phase change responsible for sickle cell disease is the result of the decrease in solubility of deoxy-B-bS as compared to the solubility of normal hemoglobin, e.g.
  • the progression from nuclear aggregation to polymer formation has a delay time inversely related to the 30 th power of the deoxy-HbS concentration.
  • the resulting polymer fibers provide additional nuclei for further polymer formation, however, the delay times usually exceed capillary transit times and so cells do not accumulate significant amounts of polymer until they are in a large vein where they cannot elicit vasoocclusion.
  • Unfortunately local vascular perturbations may cause unusual delay in the transit time and allow sickling to take place in the capillary, causing a potentially disastrous decrease in blood supply to the organ.
  • Patients with sickle cell disease can be treated with blood transfusions to reduce the concentration of abnormal hemoglobin in their circulation, however this is primarily an emergency procedure and has many disadvantages, such as transmission of infectious agents and high cost.
  • Cataracts are caused by the opacification of the crystalline lens of the eye. They are the leading cause of blindness in the world and the leading cause of visual loss in Americans older than age 40. The prevalence of cataract in the United States has been estimated at 50% for persons older than age 75. Genetic predisposition to senile cataract has been hypothesized but not proven. However, it is known that exposure to ultraviolet light, trauma to the eye, Wilson's disease or systemic corticosteroid use may all cause cataract formation.
  • cataracts are the result of a phase change in the substance of the lens causing progressive yellowing and opacification of the lens nucleus (nuclear sclerosis).
  • the normal protein matrix of the lens may cross link and precipitate over the course of time causing loss of transparency to visual light.
  • cataracts may be treated surgically by removal of the opacified lens, no agent capable of preventing the phase transition responsible for this tissue change is known.
  • the methods of this invention may be used to screen large number of agents for their ability to slow or prevent this phase transition.
  • Amyloidosis is not a single clinical entity but group of diverse diseases characterized by protein deposition. They are similar in that the protein deposition occurs extra cellularly and these deposits stain esinophilic with standard tissue histologic stains, bind Congo red dye and emit an apple-green birefringence when examined under polarized light microscopy. In addition, these protein deposits exhibit metachromasia with crystal violet and have an array of 75-100A non-brushing fibrils by electron microscopy and a twisted beta-pleated sheet antiparallel configuration by x-ray crystallography.
  • amyloid diseases differ in the biochemical nature of the proteinaceous deposits, the "etiology" of the associated diseases (neoplastic, inflammatory degenerative, hereditary), the tropism of protein deposition and the spectrum of disease manifestations.
  • All the monomeric amyloidgenic proteins have a beta-pleated sheet conformation in solution and many form insoluble beta pleated sheet fibrils in vitro. It is the formation of this periodic beta-pleated sheet that accounts for the known properties of tissue amyloid deposits such as binding to Congo red, resistance to proteolysis and insolubility in physiologic solution.
  • beta-pleated sheets in vivo is an extremely complex process involving crucial ion concentrations and hydrogen bonding between many similar monomeric polypeptide chains at high focal concentrations as well as molecular interactions with extra-cellular matrix components.
  • most amyloid deposits contain P component, an acute-phase circulating serum protein.
  • AAAA Major systemic amyloidoses 1l .. AAAA 1. Chronic inflammatory conditions K, L, S, GI, Sc a. Infectious: tuberculosis, osteomyelitis, etc. H, unusual b. Non-infectious: juvenile rheumatoid arthritis, N, rare ankylosing spondylitis, Chrohn's disease, etc.
  • a ⁇ Alzheimer's disease
  • AL amyloid was the first amyloid protein defined biochemically and shown to be identical to the variable region of immunoglobulin light chain (Bence Jones protein). AL is the most common of the amyloidoses in the U.S. and is associated with plasma cell myeloma (20%) or plasma cell dyscrasias (80%). The symptoms vary depending on organ involvement but often include ca ⁇ al tunnel syndrome, peripheral neuropathy with paresthesias of the fingers and toes and sympathetic dysfunction manifested by orthostatic hypotension and congestive heart failure.
  • AA amyloidosis was the 2 nd systemic type of amyloidosis shown to be due to protein deposition.
  • the precursor protein is a serum component called serum amyloid A that is ⁇ r synthesized in the liver.
  • the production of this protein may increase 100-200 fold following an inflammatory stimulus.
  • certain monocyte/macrophage cytokines such as interleukin 1 (LL-1), tumor necrosis factor and IL-6 may up-regulate hepatic gene expression of this protein.
  • LL-1 interleukin 1
  • tumor necrosis factor and IL-6 may up-regulate hepatic gene expression of this protein.
  • the organs most commonly involved include liver, spleen and kidney with heart and nerve involvement less frequent then seen in primary amyloidosis.
  • the infectious diseases which often trigger this form of amyloidosis include osteomyelitis, tuberculosis and bronchiectasis.
  • non-infectious inflammatory states including Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease and Familial Mediterranean Fever, can act as the triggers.
  • ATTR amyloidosis is caused by the presence of an abnormal plasma pre-albumin protein that normally functions to transport thyroxine and retinol-binding protein and was subsequently termed transthyretin. Since the discovery of this form of amyloid many different clinical manifestations resulting from the more than 50 mutations in the gene for rx transthyretin have been identified. The major organ systems involved include the heart, bowel and kidney.
  • ⁇ 2 -Microglobin is the non-covalently associated chain of class I major histocompatibility complex molecules and is present on virtually all human nucleated cells. Catabolism of this small protein depends on normal kidney filtration and excretion. In dialysis patients and those with end-stage renal disease plasma levels of ⁇ 2 -Microglobulin are elevated. The symptoms result from the deposition of this amyloid protein in periarticular, joint, bone and ca ⁇ al tunnel tissue.
  • Alzheimer's disease is the most common cause of dementia in elderly patients and afflicts between 5 and 10% of the population older than 65 years.
  • Neuropathologic studies of the brain of patients with Alzheimer's disease show neurofibrillary tangles and neuritic plaques in the amygdala, hippocampus and frontal, temporal and parietal lobes.
  • Also seen in patients with Alzheimer's disease are acellular thickening of the small and medium-sized arteries of the leptomeninges and cerebral cortex.
  • the amo ⁇ hous material in the walls of meningeal vessels and the central region of neuritic plaques has the characteristic staining property for amyloid.
  • amyloid precursor protein a novel 42-amino acid protein ( ⁇ -protein) that is generated by proteolysis of a much larger transmembrane glycoprotein termed " ⁇ amyloid precursor protein".
  • ⁇ amyloid precursor protein a transmembrane glycoprotein
  • CJD Creutzfeldt- Jakob Disease
  • Kuru Gerstmann-Straussler-Scheihker Syndrome
  • Familiar Fatal Insomnia Many of these illnesses were formerly thought to be caused by slow acting viruses.
  • PrP sc the prion protein
  • the abnormal protein configuration resists proteolytic digestion and spontaneously aggregates to produce rod like or fibrillary particles, called prion rods.
  • prion rods These structures can be isolated from the brains of animals and humans with this class of illness.
  • the clinical manifestations of CJD and other prion disease are protean and frequently incorrectly diagnosed initially.
  • the symptoms begin with altered sleep patterns and appetite, weight loss and complaints of impaired memory and concentration.
  • the diseases usually progress rapidly to global dementia, often with myoclonus and seizures. Death typically occurs within 1 year of the onset of symptoms.
  • the invention provides practical and cost-effective methods to rapidly produce and screen hundreds, thousands, to hundreds of thousands of samples per day. These methods provide an extremely powerful tool for the rapid and systematic analysis, optimization, selection, or discovery of conditions, compounds, or compositions that prevent, inhibit, induce, modify, or reverse physical-state transition.
  • the invention relates to optimization, selection, or discovery of compounds or compositions that prevent or inhibit crystallization, precipitation, formation, or deposition of inorganic and organic substances, or that promote dissolution, destruction, modification, or breakup of inorganic and organic solids, particularly disease-causing substances.
  • the invention further encompasses the use of such compounds or compositions to treat (e.g., reverse) or prevent the disease itself, the cause of the disease, or the symptoms of the disease.
  • the invention further encompasses a method for the discovery of physiological conditions (e.g., pH, salt concentration, protein concentration, hormone concentration, etc.) that inhibit or prevent crystallization, precipitation, formation, or deposition of inorganic or organic substances or that promote dissolution or breakup of inorganic and organic solids, particularly disease-causing substances.
  • physiological conditions e.g., pH, salt concentration, protein concentration, hormone concentration, etc.
  • the invention further contemplates the use of drugs or other therapies to achieve these physiological conditions, and thereby prevent or treat the disease itself, the cause of the disease, slow or modify progression of the disease, or the symptoms of the disease.
  • the invention also encompasses methods to discover compounds, compositions, or physiological conditions that prevent or inhibit a change in physical state of a solid substance, for example, prevention or inhibition of a polymo ⁇ hic shift of a benign solid to a disease-causing substance or mineralization of a plaque to form a disease-causing substance.
  • the invention further encompasses methods to discover compounds, compositions, or physiological conditions that prevent or inhibit unfavorable biocrystallization or bioprecipitation of pharmaceuticals, such as physiologically low-solubility pharmaceuticals or pharmaceuticals that complex with tissue or other bodily substances.
  • the invention encompasses methods to discover compounds, compositions, or physiological conditions that promote, potentiate, or induce a change in physical state. For example, promotion of bone growth or mineralization.
  • the invention comprises arrays for screening to identify conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state comprising at least 24 samples, each sample comprising a medium, wherein one or more of the samples comprises a disease-causing substance.
  • the invention concerns a method of preparing an array of at least 24 samples for screening to identify conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state comprising:
  • the invention relates to a method of screening an array of at least 24 samples to identify conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state comprising:
  • the invention concerns a method to discover conditions, compounds, or compositions that prevent or inhibit crystallization, precipitation, or deposition of a disease-causing substance, comprising:
  • the invention comprises a method to discover conditions, compounds or compositions that promote dissolution, destruction, or breakup of a disease- causing substance, comprising:
  • the samples are prepared in a grid or array (i.e., an ordered set of components) such as a 25, 48 or 96 well plate.
  • Each sample in the array comprises a medium and at least one of the samples comprises a disease-causing substance, in solid, liquid, or dissolved form.
  • the array or selected samples therein can be subjected to processing parameters.
  • processing parameters include temperature, temperature gradient, time, the identity or the amount of the disease-causing substance, the identity or the amount of the medium, or the identity or the amount of the components.
  • each sample in the processed array can be screened to determine whether a change in physical state occurred, particularly a change in the physical state of a disease-causing substance.
  • the presence or absence of a solid can be assessed by turbidity, using a device such as a spectrophotometer. But a simple visual analysis can also be conducted including photographic analysis. Crystal forms, different polymo ⁇ hs, and other amo ⁇ hous solids are then determined.
  • the samples containing a solid can then be screened to analyze the solid's properties, such as structural, physical, pharmacological, or chemical properties.
  • the samples are screened to define the conditions, compounds, or compositions, that prevent or inhibit crystallization, precipitation, formation, or deposition of inorganic and organic substances, or that promote dissolution, destruction, or breakup of inorganic and organic solids, particularly disease-causing substances.
  • Systems employing these methods have been designed to rapidly, systematically, and inexpensively screen such samples. The methods and systems are widely applicable. 4.1 Helpful Definitions
  • the term "array" means a plurality of samples, preferably, at least 24 samples. Each sample comprises a medium, and at least one of the samples comprises a disease-causing substance. Preferably, each sample comprises the disease-causing substance, with the exception of negative controls. Each sample can have different components or concentrations of components. The samples are associated under a common experiment.
  • An array can comprise 24, 36, 48, 96, or more samples, preferably 1000 or more samples, more preferably, 10,000 or more samples.
  • An array is typically comprised of one or more groups of samples also known as sub-arrays.
  • a sub-array can be a 96-tube plate of sample tubes or a 96- well plate of sample wells in an array comprising 100 plates.
  • Arrays can be assembled by preparing a plurality of samples using standard addition and mixing techniques. If desired, each sample, selected samples, or selected sub-arrays can be subjected to the same or different processing parameters. For example, an array can be processed to prevent or inhibit crystallization, precipitation, formation, or deposition of the disease-causing substance, or to promote dissolution, destruction, or breakup of the disease- causing substance. Arrays can be processed by a variety of methods readily ascertainable by one skilled in the art according to the objective of the experiment. For example, the array can be stored at a particular temperature, such as room temperature. The samples can be subjected to a temperature gradient, such as cooling the sample. Or the pH can be adjusted by adding acidic or basic components.
  • the array can also be subjected to standard methods well known in the art to prevent or inhibit crystallization, precipitation, formation, or deposition of the disease-causing substance, or that promote dissolution, destruction, or breakup of the disease-causing substance, for example, but not limited to, ultrasound, shock-waves, or laser energy.
  • Disease-causing substance means any solid, semisolid, paste, gel, plaque, or liquid in dissolved or undissolved form, that can crystalize, precipitate, or otherwise accumulate or deposit in solid form in an animal body, thereby causing or aggravating a disease process.
  • disease-causing substances include, but are not limited to, calcium salts and compositions thereof, such as calcium phosphate, calcium carbonate, calcium pyrophosphate, brushite, apatite, hydroxyapatite, calcium oxalate, kidney stones, and bone tissue; magnesium salts and compositions thereof, such as magnesium ammonium phosphate; uric acid and salts thereof; cholesterol and cholesterol compositions, such as cholesterol gall stones; bilirubin, salts thereof, and compositions thereof, such as pigment gall stones; or hydrates and mixtures thereof; tooth plaque; dental calculus; and protein precipitates, such as amyloid protein deposits.
  • calcium salts and compositions thereof such as calcium phosphate, calcium carbonate, calcium pyrophosphate, brushite, apatite, hydroxyapatite, calcium oxalate, kidney stones, and bone tissue
  • magnesium salts and compositions thereof such as magnesium ammonium phosphate
  • uric acid and salts thereof such as cholesterol and cholesterol compositions, such as cholesterol
  • Disease-causing substances can form in vivo — and thus can be isolated from an animal, plant, tissue, or cell culture — or they can be prepared in a laboratory setting to mimic one or more physical, chemical, or structural properties of those formed in vivo.
  • Disease-causing substances derived from animals and plants are often complex mixtures, thus, those prepared in a laboratory setting will usually only approximate those formed in vivo.
  • the term "medium” is the solution in which the inhibition or promotion of various phase transitions or changes of physical state are tested.
  • a medium will be chosen to mimic the physiologic conditions under which such changes occur in vivo.
  • the precise composition of the medium will depend on which phase transition or change in physical state is being investigated.
  • the formation of renal calculi will be investigated in solutions that are similar to the composition of urine in various parts of the kidney and bladder.
  • the formation of gallstones will be investigated in a medium that reproduces the conditions that occur in normal bile and the bile that occurs in various disease states such as hypercholesterolemia and hypocalcemia.
  • the changes in physical state that result in tissue calcification may be investigated in mediums that are similar in composition to blood plasma, or to the fluid in the extracellular or intracellular spaces, in joints spaces or in saliva in normal and various disease states.
  • mediums that are similar in composition to blood plasma, or to the fluid in the extracellular or intracellular spaces, in joints spaces or in saliva in normal and various disease states.
  • One of skill in the art will be aware that the exact composition of the medium employed will depend on the nature of the phase transition or change in physical state being investigated, but will be primarily water based. These solutions may vary in pH, electrolyte concentration, protein concentration, and the presence or absence of various organic and inorganic compounds such as cholesterol, bile salts, sodium, potassium, calcium ions or mucins, polysaccarides or proteins.
  • These media may be obtained from natural sources such as blood plasma, urine, bile and joint space fluid or can be prepared by means well known to one of ordinary skill in the art.
  • sample means at least a medium isolated at a particular location or site, preferably, further comprising a disease-causing substance.
  • a sample can comprise multiple disease-causing substances.
  • a sample can comprise one or more components.
  • the amount of the disease-causing substance is less than about 100 milligrams, more preferably, less than about 1 milligram, even more preferably, less than about 100 micrograms.
  • the sample has a total volume of about 5 ⁇ l to about 500 ⁇ l, more preferably, about 10 ⁇ l to about 200 ⁇ l.
  • a sample can be contained in any container or holder, or present on any material or surface, or absorbed or adsorbed in any material or surface. The only requirement is that the samples are isolated from one another, that is, located at separate sites. In one embodiment, samples are contained in sample wells in standard sample plates, for instance, in 24, 36, 48, or 96 well plates (or filter plates) of volume 250 ul commercially available, for example, from Millipore, Bedford, MA.
  • the samples can be contained in glass sample tubes, for example, individual glass tubes in a metal support plate.
  • the tube is equipped with a plunger seal having a filter frit on the plunger top.
  • the medium and other substances or components are distributed in the tubes, and the tubes sealed.
  • the sealing is accomplished by capping with a plug-type cap.
  • both the plunger and cap are injection molded from thermoplastics, ideally chemically resistant thermoplastics such as PFA (although polyethylene and polypropylene are normally sufficient).
  • PFA polyethylene and polypropylene are normally sufficient.
  • any solid can be separated from the medium.
  • the plunger is then forced up the tube, effectively scraping any solid substance present on the walls, thereby collecting the solid substance on the frit.
  • the plunger is fully extended at least to a level where the frit, and any collected solid substance, are fully exposed above the tube. This allows the frit to be inserted into the under-side of a custom etched glass analysis plate.
  • This analysis plate has 96 through-holes etched corresponding to the 96 individual frits.
  • the top-side of the analysis plate has an optically clear glass plate bonded onto it to both seal the plate as well as provide a window for analysis.
  • the analysis plate assembly which contains the plate itself plus the added frits with the solid substance, can be stored at room temperature, under an inert atmosphere if desired.
  • the individual sample tube components are readily constructed from HPLC auto-sampler tube designs, for example, those of Waters Co ⁇ (Milford, MA).
  • HPLC auto-sampler tube designs for example, those of Waters Co ⁇ (Milford, MA).
  • the automation mechanisms for capping, sealing, and sample tube manipulation are readily available to those skilled in the art of industrial automation.
  • the amounts or the identity of the medium, the components, or the disease-causing substance can vary between samples. For example, within an individual array or sub-array, one or more of the samples can differ from one or more of the other samples with respect to: (i) the identity or the amount of the disease-causing substance;
  • component means any substance that is combined, mixed, or processed in the medium comprising a sample.
  • a single component can exist in one or more physical states.
  • suitable components include, but are not limited to, compounds and compositions that prevent or inhibit precipitation, formation, crystallization, or nucleation of inorganic and organic substances, such as pyrophosphate and citric acid salts; compositions and compounds that promote dissolution, etching, destruction, or breakup of inorganic and organic solids; nucleation promoters (also known as crystallizing aids), such as seed crystals or surfactants, and combinations thereof; compositions or compounds that affect crystal habit; nutrients, such as vitamins and minerals; small molecules (i.e., molecules having a molecular weight of less than about 1000 g/mol), such as pharmaceuticals (e.g., ursodeoxycholic acid; diuretic agents, thiazides, and allopurinol); large molecules (i.e., molecules having a molecular
  • component also encompasses disease-causing solids, which, as discussed herein, can be added to samples according to certain embodiments of the invention.
  • component further encompasses the ingredient or one of the ingredients in the sample medium — in dissolved or undissolved form — that can induce or result in crystallization, precipitation, formation, or deposition of a disease-causing substance within the sample.
  • processing parameters means the physical or chemical conditions under which a sample is subjected and the time during which the sample is subjected to such conditions.
  • the period of incubation is also a processing parameter and means the time that a sample is given to undergo a change in physical state.
  • processing parameters include, but are not limited to, adjustments in time of incubation, temperature, pressure, pH, chemical environment, subjecting the samples to a nucleation event, ultrasound, shock waves, laser energy, or mechanical stimulation, or any other conditions that can induce a change in physical state.
  • Processing also includes adjusting the concentration of components, adding various additional components, or adjusting the composition or amount of the medium during incubation. Processing also includes parameters such as adjusting the oxygen tension or oxygen vapor pressure.
  • a sample can be processed to prevent or inhibit crystallization, precipitation, formation, or deposition of inorganic and organic substances, or to promote dissolution, destruction or breakup of existing inorganic and organic solids, particularly disease-causing substances.
  • Sub-arrays or even individual samples within an array can be subjected to processing parameters that are different from the processing parameters to which other sub-arrays or samples, within the same array, are subjected.
  • Processing parameters will differ between sub-arrays or samples when they are intentionally varied to induce a measurable change in the sample's properties.
  • minor variations such as those introduced by slight adjustment errors, are not considered intentionally varied.
  • the term "property” means a structural, physical, pharmacological, or chemical characteristic of a sample, preferably, a structural, physical, pharmacological, or chemical characteristics of a disease-causing substance in a sample.
  • Structural properties include, but are not limited to, whether the disease-causing substance is crystalline or amo ⁇ hous, and if crystalline, the polymo ⁇ hic form and a description of the crystal habit. Structural properties also include the composition, such as whether the disease-causing substance is a hydrate, solvate, or a salt and whether the substance is mineralized, the degree of mineralization, and identity of the minerals. Another important structural property is the surface-to-volume ratio and the degree of agglomeration of the particles.
  • Surface-to-volume ratio decreases with the degree of agglomeration. It is well known that a high surface-to-volume ratio improves the solubility rate and ease of bodily elimination of a disease-causing substance. Small-size particles have high surface-to-volume ratio.
  • the surface-to-volume ratio is also influenced by the crystal habit, for example, the surface-to-volume ratio increases from spherical shape to needle shape to dendritic shape. Porosity also affects the surface-to-volume ratio, for example, disease-causing substances having channels or pores (e.g., inclusions, such as hydrates and solvates) have a high surface-to-volume ratio. Still another structural property is particle size and particle-size distribution.
  • particles can form from solution in different sizes and size distributions.
  • Particulate matter produced by precipitation or crystallization, has a distribution of sizes that varies in a definite way throughout the size range.
  • Particle- and crystal-size distribution is generally expressed as a population distribution relating to the number of particles at each size.
  • particle and crystal size distribution have very important clinical aspects. For example, smaller particles are more easily eliminated from the body and have higher surface-to-volume ratio that allows easier dissolution in bodily fluids.
  • compounds or compositions that promote small crystal size can be of clinical importance in treating or preventing diseases caused by solid deposits in the body.
  • Pharmacological properties include, but are not limited to, toxicity and metabolic profile.
  • Physical properties include, but are not limited to, melting point, solubility, strength, hardness, compressibility, compactability, and resistance to energy forms, such as ultrasound, shock waves, and laser energy.
  • Physical stability refers to a compound's or composition's ability to maintain its physical form, for example maintaining particle size; maintaining crystal or amo ⁇ hous form; maintaining complexed form, such as hydrates and solvates; resistance to abso ⁇ tion of ambient moisture; and maintaining of mechanical properties, such as compressibility and flow characteristics.
  • Methods for measuring physical stability include spectroscopy, sieving or testing, microscopy, sedimentation, stream scanning, and light scattering. Polymo ⁇ hic changes, for example, are usually detected by differential scanning calorimetry or quantitative infrared analysis.
  • Flow properties of particles through liquids is also a relevant physical property.
  • flow properties of disease-causing solids in bodily fluids and compartments dictates the distribution in and ease of elimination from the body.
  • red blood cells deformed by sickle-cell protein have very poor flow characteristics through capillaries.
  • flow properties can be influenced by a number of factors, such as size and size distribution, shape, habit, polymo ⁇ h, and porosity, etc.
  • Chemical properties include, but are not limited to chemical stability, such as susceptibility to oxidation and reactivity with other compounds, such as acids, bases, or chelating agents. Chemical stability refers to resistance to chemical reactions induced, for example, by heat, ultraviolet radiation, moisture, chemical reactions between components, or oxygen.
  • Well known methods for measuring chemical stability include mass spectroscopy, UN-NIS spectroscopy, HPLC, gas chromatography, and liquid chromatography-mass spectroscopy (LC-MS).
  • mass spectroscopy UN-NIS spectroscopy
  • HPLC gas chromatography
  • LC-MS liquid chromatography-mass spectroscopy
  • the "physical state" of a substance is initially defined by whether it is in solid, liquid, or dissolved form.
  • the physical state is further defined by the particle or crystal size, the particle-size distribution, the degree of agglomeration and the habit.
  • Physical state can further be defined by purity of the solid substance, for example, whether the substance is mineralized, the degree of mineralization, and identity of the minerals.
  • Mechanisms by which impurities can be inco ⁇ orated in solid substances include surface abso ⁇ tion and entrapment in cracks and crevices, especially in agglomerates and crystals.
  • Physical state includes whether the substance is crystalline or amo ⁇ hous. If the substance is crystalline, the physical state is further divided into: (1) whether the crystal matrix includes a co-adduct; (2) mo ⁇ hology, i.e., crystal habit; and (3) internal structure (polymo ⁇ hism).
  • the crystal matrix can include either a stoichiometric or non-stoichiometric amount of the adduct, for example, a crystallization solvent or water, i.e., a solvate or a hydrate.
  • Non-stoichiometric solvates and hydrates include inclusions or clathrates, that is, where a solvent or water is trapped at random intervals within the crystal matrix, for example, in channels.
  • a stoichiometric solvate or hydrate is where a crystal matrix includes a solvent or water at specific sites in a specific ratio. That is, the solvent or water molecule is part of the crystal matrix in a defined arrangement. Additionally, the physical state of a crystal matrix can change by removing a co-adduct, originally present in the crystal matrix. For example, if a solvent or water is removed from a solvate or a hydrate, a hole is formed within the crystal matrix, thereby forming a new physical state. Such physical states are referred to herein as dehydrated hydrates or desolvated solvates.
  • the crystal habit is the description of the outer appearance of an individual crystal, for example, a crystal may have a cubic, tetragonal, orthorhombic, monoclinic, triclinic, rhomboidal- or hexagonal shape.
  • the internal structure of a crystal refers to the crystalline form or polymo ⁇ hism.
  • a given compound may exist as different polymo ⁇ hs, that is, distinct crystalline species.
  • different polymo ⁇ hs of a given compound are as different in structure and properties as the crystals of two different compounds. Solubility, melting point, density, hardness, crystal shape, optical and electrical properties, vapor pressure, and stability, etc. all vary with the polymo ⁇ hic form.
  • the array technology described herein is a high-throughput approach that can be used to generate large numbers (greater than 10, more typically greater than 50 or 100, and more preferably 1000 or greater samples) of parallel small scale samples.
  • the basic requirements for array and sample preparation and screening thereof are: (1) a distribution mechanism to add components and the medium to separate sites, for example, on an array plate having sample wells or sample tubes.
  • the distribution mechanism is automated and controlled by computer software and can vary at least one addition variable, e.g., the identity of the component(s) and/or the component concentration, more preferably, two or more variables.
  • Such material handling technologies and robotics are well known to those skilled in the art.
  • individual components and the medium can be placed at the appropriate sample site manually. This pick and place technique is also known to those skilled in the art.
  • a screening mechanism to test each sample to detect a change in physical state or for one or more properties.
  • the testing mechanism is automated and driven by a computer.
  • the system further comprises a processing mechanism to process the samples after component addition.
  • An array can be prepared, processed, and screened as follows.
  • the first step comprises selecting the medium and component sources, preferably, at one or more concentrations.
  • at least one component source can deliver a disease-causing substance. That is, one component source should comprises at least one of: a disease- causing substance in undissolved form; a disease-causing substance in dissolved form; or the components necessary ⁇ — in dissolved or undissolved form— to induce a disease-causing substance.
  • adding the medium and the components to a plurality of sample sites, such as sample wells or sample tubes on a sample plate to give an array of unprocessed samples.
  • the array can be processed according to the pu ⁇ ose and objective of the experiment, and one of skill in the art will readily ascertain the appropriate processing conditions.
  • the samples can be processed by heating, cooling, adding additional components, such as acids or bases, stirring, milling, filtering, centrifuging, emulsifying, or by simply allowing the samples to stand for a period of time at a specified temperature, for example, at normal human-body temperature.
  • Each sample in array can be screened to determine the presence or absence of a disease-causing substance and thereafter testing the disease- causing substance for one or more properties.
  • the data so collected is stored for subsequent data analysis, preferably, by a computer.
  • the automated distribution mechanism used in accordance with the invention can distribute or add components in the form of liquids, solids, semi-solids, gels, foams, pastes, ointments, suspensions, or emulsions.
  • Solids can be in any form, for example, powders, tablets, or pellets.
  • the components are solids — for example, nucleating inhibitors, pharmaceuticals, etc. or a component designed to mimic one or more of the properties of a particular disease-causing substance (e.g., calcium phosphate) — preferably, they are in the form of micropellets or microtablets, prepared by micropelleting or microtableting.
  • a disease-causing substance e.g., calcium phosphate
  • the solid when it is a disease-causing substance, it can be in is natural form, i.e., as isolated from an animal, plant, cell, or tissue, for example, animal gall stones, kidney stones, protein deposits, or dental buildup.
  • Micropellets can be prepared using standard pharmaceutical-tableting machines, modified as appropriate.
  • the tableting machine comprises a small die, of from about 1/16" to about 3/16" in diameter. Any required modifications are easily made by those skilled in the art. With the appropriate modification, the microtableting machine can make microtablets of almost any solid component.
  • the component is a pharmaceutical, it can be dispersed within a matrix of a compressible, inert carrier material, such as potassium chloride or pelleted in the absence of an inert carrier.
  • Another method of forming micropellets involves forcing a paste comprising a component or a component mixed with an inert carrier into a mold, drying the paste, and then ejecting the pellet.
  • the component to be pelleted is first homogenized with a solvent or a solvent and an inert carrier.
  • a solvent or a solvent and an inert carrier Preferably, when an inert carrier is used, it is lactose or mannitol.
  • Any solvent is suitable and readily selected by one skilled in the art depending on the component.
  • the solvent is relatively volatile, more preferably having a boiling point of less than 100 °C, for example, alcohols such as methanol or ethanol.
  • the ratio of solvent to component/inert carrier mixture is of from about 10:1 to about 1:10, more preferably about 6:1 to about 1:1, even more preferably, from about 5 : 1 to about 3:1.
  • the component, solvent, and inert carrier if present are homogenized to a paste and the solvent is then removed at reduced pressure to yield a dry powder.
  • the powder is then mixed with another solvent, preferably water, to form a homogeneous paste, which paste is forced into individual tube shaped molds.
  • the dimensions of the molds is from about 1/16" to about 3/16" in depth, preferably, about 1/8" in depth and from about 1/32" to about 1/8" in inner diameter, preferably, about 5/64" inner diameter.
  • the pastes are allowed to dry for about 1 minute to about 5 hours, preferably, for about 5 minutes to about 1 hour, more preferably, for about 10 minutes; at a temperature of from about 15 °C to about 100 °C, more preferably, from about 20 °C to about 30 °C; at a pressure of from about 10 mm/Hg to about 1000 mm Hg, preferably, at about 20 mm/Hg.
  • the paste-in-mold is allowed to dry for about 10 minutes, at about room temperature, and at about atomospheric pressure.
  • the dried paste in the form of a micropellet is then ejected from the molds, preferably, by inserting a flat head pin through the mold, the pin being of about the same diameter, preferably of just a slightly smaller diameter than the inner diameter of the mold.
  • the molded micropellets can then be dried under reduced pressure, preferably, for from about 6 to about 24 hours, more preferably, about 12 hours; at a temperature of from about 15 °C to about 100 °C, preferably at about room temperature; and at a pressure of from about lOmm/Hg to about 1000 mm Hg, preferably, about 20 mm/Hg.
  • a preferred automated mechanism for adding solid components, preferably micropellets, to sample sites comprises reservoirs or bins, for each component.
  • the outlet of these bins is controlled so that an individual microtablet is "singulated” and able to be dispensed to a specified sample site in an array.
  • a system where a solid component source, such as a disease- causing-solid source or a solid-component source and a liquid-distribution source, such as a medium source or a liquid-component source automatically distribute the respective solids or liquids to the sample sites, such as sample wells in a 96 well filter plate (commercially available, for example, from Millipore, Bedford, MA) to give a plurality of samples.
  • the combinations of the medium and various components at various concentrations or combinations are generated using standard software (e.g., Matlab software, commercially available from Mathworks, Natick, Massachusetts). The combinations thus generated can be downloaded into a spread sheet, such as Microsoft EXCEL.
  • a worklist can be generated for instructing the automated distribution mechanism to prepare an array of samples according to the various combinations generated by the formulating software.
  • the worklist can be generated using standard programming methods according to the automated distribution mechanism employed. The use of so-called worklists simply allows a file to be used as the process command rather than discrete programmed steps.
  • the worklist combines the formulation output of the formulating program with the appropriate commands in a file format that directly readable by the automatic distribution mechanism.
  • the automated distribution mechanism can deliver multiple amounts of each component.
  • Automated liquid distribution mechanisms are well known and commercially available, such as the Tecan Genesis, from Tecan-US, RTP, North Carolina. Automated solid distribution mechanisms are readily obtained by modifying commercially available robotics systems.
  • the sealing mechanism can be a glass plate with an integrated chemically compatible gasket. This mode of sealing allows visual inspection of each sample.
  • Processing includes mixing; agitating; heating; cooling; adjusting the pressure; adding additional components, such as acids or bases; stirring; milling; filtering; centrifuging, emulsifying, subjecting one or more of the samples to mechanical stimulation; ultrasound; shock waves; or laser energy; or allowing the samples to stand for a period of time at a specified temperature; for example, normal human-body temperature.
  • the array can be processed by heating to a temperature (TI), preferably to a temperature at which the all the solids are completely in solution.
  • TI a temperature at which the all the solids are completely in solution.
  • the samples are then cooled, to a lower temperature T2, usually for at least one hour.
  • T2 a temperature at which the all the solids are completely in solution.
  • the samples can be processed by introducing a nucleation event.
  • Nucleation events include mechanical stimulation and exposure to sources of energy, such as acoustic (ultrasound), electrical, or laser energy. Nucleation can also be induced by adding components that decrease the surface energy. During cooling, each sample is analyzed for the presence of solid formation. This analysis allows determination of the precipitation or crystallization temperature.
  • samples in commercially available microtiter plates can be screened for the presence of solids (e.g., precipitates or crystals) using automated plate readers.
  • Automated plate readers can measure the extent of transmitted light across the sample. Diffusion (reflection) of transmitted light indicates the presence of a precipitate. Visual examination of these plates can also be used to detect the presence of solids.
  • the plates can be scanned for precipitation by measuring turbidity. If desired, samples containing solids can be filtered to separate the solids from the medium, resulting in an array of filtrates and an array of solids.
  • the filter plate comprising the suspension is placed on top of a receiver plate containing the same number of sample wells, each of which corresponds to a sample well on the filter plate.
  • a receiver plate containing the same number of sample wells, each of which corresponds to a sample well on the filter plate.
  • the liquid phase of the filter plate is forced through the filter on the bottom of each sample well, into the corresponding sample well of the receiver plate.
  • the appropriated centrifuge is available commercially, for example, from DuPont, Wilmington, DE.
  • the receiver plate is designed for analysis of the individual filtrate samples.
  • Different temperatures can be used during the solid growth phase. Typically, several distinct temperatures are tested during solid precipitation and crystal nucleation.
  • Temperature can be controlled in either a static or dynamic manner.
  • Static temperature means that a set incubation temperature is used throughout the solid formation process.
  • a temperature gradient can be employed. For example, the temperature is decreased or raised at a constant rate throughout the solid formation.
  • Stand-alone devices employing Peltier-effect cooling and joule-heating are commercially available for use with microtiter plate footprints.
  • a standard thermocycler used for PCR such as those manufactured by MJ Research or PE Biosystems, can also be used to accomplish the temperature control. The use of these devices, however, necessitates the use of conical vials of conical bottom micro-well plates.
  • full-scale systems such as the advanced Chemtech Benchmark Omega 96TM or Venture 596 TM would be the platforms of choice. Both of these platforms utilize 96-well reaction blocks made from TeflonTM. These reaction blocks can be rapidly and precisely controlled from -70 to 150°C with complete isolation between individual wells. Also, both systems can operate under an inert atmosphere and utilize chemically-inert handling elements.
  • the Omega 496 system has simultaneous independent dual coaxial probes for liquid handling, while the Venture 596 system has 2 independent 8-channel probe heads with independent z-control. Moreover, the Venture 596 system can process up to 10,000 reactions simultaneously. Both systems offer complete autonomy of operation.
  • Supersaturation is the thermodynamic driving force for both crystal nucleation and growth and thus is a key variable in processing arrays. Supersaturation is defined as the deviation from thermodynamic solubility equilibrium. Thus the degree of saturation can be controlled by temperature and concentrations and identities of components. In general, the degree of saturation can be controlled in the metastable region, when the metastable limit has been reached, nucleation will be induced.
  • Crystal nucleation is the formation of a crystal solid phase from a liquid or amo ⁇ hous phase. Nucleation sets the character of the crystallization process. So called primary nucleation can occur by heterogenous or homogeneous mechanisms. Primary nucleation does not involve existing crystals, but results from spontaneous crystal formation. Primary nucleation can be induced by increasing the saturation over the metastable limit or, when the degree of saturation is between supersaturation and the metastable, by introducing a nucleation event. Nucleation events include mechanical stimulation and exposure to sources of energy, such as acoustic (ultrasound), electrical, or laser energy. Primary nucleation can also be induced by adding primary nucleation promoters, that is substances other than the substance to be crystallized.
  • nucleation can be controlled by adjusting the interfacial tension of the crystallizing medium by introducing surfactant-like molecules either by pre-treating the sample tubes or sample wells or by direct addition.
  • the nucleation effect of surfactant molecules is dependent on their concentration and thus this parameter should be carefully controlled.
  • tension adjusting additives are not limited to surfactants.
  • Many compounds that are structurally related to the compound to be crystallized can have significant surface activity.
  • heterogeneous nucleation inducing additives include solid particles of various substances, such as solid-phase excipients or impurities.
  • inorganic crystals on specifically functionalized self-assembled monolayers have also been demonstrated to induce nucleation by Wurm, et ⁇ /.,1996, J. Mat. Sci. Lett. 15:1285 (1996).
  • Nucleation of organic crystals such as 4-hydroxybenzoic acid monohydrate on a 4-(octyldecyloxy)benzoic acid monolayer at the air- water interface has been demonstrated by Weissbuch, et al. 1993 J. Phys. Chem. 97:12848 and Weissbuch, et al, 1995 /. Phys. Chem. 99:6036.
  • Nucleation of ordered two dimensional arrays of proteins on lipid monolayers has been demonstrated by Ellis et al, 1997, J. Struct. Biol. 118:178.
  • Secondary nucleation involves treating the crystallizing medium with a secondary nucleation promoter, that is crystals of the compound to be crystalized itself.
  • a secondary nucleation promoter that is crystals of the compound to be crystalized itself.
  • Direct seeding of samples with a plurality of nucleation seeds in various physical states provides a means to induce formation of different crystal forms.
  • particles are added to the samples.
  • nanometer-sized crystals nanoparticles
  • Particle size is very relevant to the clinical aspects of disease- causing solids.
  • Particle size and size distribution often dictate the pathology of disease- causing solids.
  • the body has variable responses to pathogenic particles depending on size and size distribution, such as immune response and whether osteocytes or macrophages are activated.
  • Particulate matter, produced by precipitation or crystallization has a distribution of sizes that varies in a definite way throughout the size range.
  • Particle- and crystal-size distribution is generally expressed as a population distribution relating to the number of particles at each size. In disease-causing substances, particle and crystal size distribution have very important clinical aspects.
  • the particle size of substances formed by crystallization or precipitation from solvents or other fluids, such as bodily fluids is influenced by a number of factors, such as nucleation, number of nucleation sites, degree of saturation of the substance, solubility of the substance.
  • the structure of the formed precipitate or crystals also influences particle size and size distribution. Structural properties, such as habit, polymo ⁇ h, porosity, and composition can affect crystal size in many ways, such as providing additional nucleation sites and affecting the growth rate.
  • Samples can be incubated for various lengths of time. Since physical-state changes, particularly crystallizations, can occur as a function of time, it is advantageous to examine arrays over a range of times.
  • the charge of the compound being precipitated or crystallized can determine the nature of the solid phase that is generated.
  • the pH can be modified by the addition of inorganic and organic acids and bases, additional crystallization additives such as small molecules, macromolecules, and solvents.
  • solvents or mixtures of solvents can inhibit or promote physical- state changes and influence the type of physical state change, such as whether crystals or a precipitate is generated.
  • Solvents may influence and direct the formation of the solid phase through electrostatic properties, charge distribution, molecular shape and flexibility, and pH. Solvents accepted for use in drug manufacture are preferred for use in the arrays of the invention. Various mixtures of those solvents can be used. Solvents include, but are not limited to, aqueous-based solvents such as water, aqueous acids, bases, salts, and buffers or mixtures thereof and organic solvents, such as protic, aprotic, polar or non-polar organic solvents.
  • the concentration of the components can influence, promote, or inhibit changes in physical state, for example, whether a crystal or a precipitate is formed.
  • the temperature at which crystallization is thermodynamically possible is generally a strong function concentration. Crystal-growth rate increases with increasing concentration, which can affect crystal habit. For example, rapid growth must accommodate the release of the heat of crystallization. This heat effect is responsible for the formation of dendrites during crystallization. The macroscopic shape of the crystal is profoundly affected by the presence of dendrites and even secondary dendrites.
  • concentration of components is the chemical composition of the crystal or precipitate formed. For example, a concentrated solution may first form crystals of the hemihydrate when precipitated from aqueous solution at high temperature. The dihydrate may, however, be the first to form when starting with a dilute solution.
  • Viscosity and Rheologv The viscosity and rheology of biomolecules is an important target for providing treatment in various disease states. Influencing, modifying, promoting, or inhibiting changes in physical state, for example, can modulate viscosity and rheological properties in a desirable manner. For instance, microtubules interconvert stochastically between polymerization and depolymerization of tubulin. Substances affecting microtubule dynamics, such as paclitaxel and colchicin, have important therapeutic properties.
  • the methods of the invention encompass high-throughput screening for compounds that induce polymerization or depolymerization of microtubules, and the use of certain compounds identified by the methods of the invention to treat diseases associated with microtubule polymerization.
  • Such compounds may further increase the efficacy of DNase administered to lower the viscosity for more effective clearance of the airways.
  • more effective formulations of DNase and other treatments are possible by screening methods taught by the instant application.
  • the methods of the invention encompass high-throughput screening for compounds that induce dis-aggregation of DNA, and the use of certain compounds identified by the methods of the invention to treat diseases associated with DNA aggregation.
  • Rheological properties of human semen provide yet another example of the application of such considerations in a biological context is provided by human semen.
  • Human semen exhibits high viscosity and an almost gel like behavior soon after ejaculation, see, e.g., Dunn et al, 1977, Int. J. Infertil, 22:217.
  • Mandal et al, 1985, Andrologia, 17:228 describe the liquefaction of the ejaculate coagulum with modification of fibers into globular bodies that fuse to form the homogenous liquified semen. This process is known to include several steps, e.g., Koren et al, 1979, J. Reprod.
  • the methods of the invention encompass high-throughput screening for compounds that modulate liquefaction of human semen, and the use of certain compounds identified by the methods of the invention to treat diseases associated with semen liquifaction.
  • Screening for safe and effective inhibitors of the liquefaction by assaying the flow properties of a semen-coagulum in accordance with the described invention can yield safer and effective compounds and formulations with many applications.
  • Such compounds and formulations can be provided, for instance, externally in suppositories or creams and the like, for providing birth control since liquefaction is required for further migration of sperms in the female reproductive system following deposition therein.
  • compounds and formulations promoting liquefaction of the sperm-coagulant are also useful as a potentially safe aid for increasing the likelihood for pregnancy and are likely to be readily identified by screens in accordance with the invention described herein.
  • the methods of the invention encompass high-throughput screening for compounds that induce liquefaction of human semen, and the use of certain compounds identified by the methods of the invention to treat diseases and conditions associated with semen to liquefaction.
  • the samples are analyzed to detect those samples wherein a change in physical state occurred.
  • the sample's filtrate can be analyzed to detect or measure concentrations of dissolved substances, for example, the concentration of a dissolved disease-causing solid.
  • Solubility can be analyzed using devices, such as UN-Vis spectroscopy (using plate-based readers known to those skilled in the art, an example of which is the SpectraMax Plus from Molecular Devices, Sunnyvale, CA), GC, HPLC, and LC-MS.
  • UN-Vis spectroscopy using plate-based readers known to those skilled in the art, an example of which is the SpectraMax Plus from Molecular Devices, Sunnyvale, CA
  • GC SpectraMax Plus from Molecular Devices, Sunnyvale, CA
  • solid materials present in the samples are analyzed, such as solid disease-causing substances.
  • suitable methods of analysis include, but are not limited to, x-ray diffraction crystallography, such as single crystal or powder x-ray diffraction; second harmonic generation (SGH); microscopy; photomicrography; thermal methods of analysis, such as thermogravimetric analysis (TGA) and differential thermal analysis (DTA); electron microscopy; infrared spectroscopy; and analytical methods requiring dissolution of the solid, such as ultraviolet spectroscopy, nuclear magnetic resonance (NMR) spectroscopy; polarography; gas chromatography; and high-pressure liquid chromatography (HPLC).
  • Solids can also be analyzed by subjecting them to energy forms, such as laser, ultrasound, or shock waves to determine their resistance thereto.
  • Other analytical devices that can be used with the methods and arrays of the invention include pH sensors, ionic strength sensors, optical spectrometers, devices for measuring turbidity, calorimeters, infrared spectrometers, polarimeters, radioactivity counters, conductivity measurers, and heat of dissolution measurers.
  • Data collection and storage preferably, are performed by computers using the appropriate software. Such computers and software are readily chosen by one of skill in the art.
  • the data is typically collected and stored directly from the analytical equipment using software provided by the instrumentation's manufacturer.
  • the data set can then be downloaded to a database for analysis.
  • Data analysis can be performed using visualization software, such as SPOTFIRE
  • the visualized data can be analyzed directly to arrive at optimized conditions, compounds, or compositions. Or the data can be processed through data mining algorithms so as to optimize the ability of scientific personnel to detect complex multi-dimensional interactions or lack of interactions between components or to conduct future experiments to optimize the formulations.
  • suitable data-mining software include, but not limited to, SPOTFIRE; MATLAB (Mathworks, Natick, Massachusetts); STATISTICA (Statsoft, Tulsa, Oklahoma). All resulting analysis files are stored on a central file server, i.e., a data base, where the files can be accessed by traditional means known to those skilled in the art.
  • solids such as solid disease-causing substances generated samples can be detected and analyzed. There are several general methods applicable. After a solid is detected it can be further analyzed to define its physical state.
  • so-called machine vision technology is used.
  • images are captured by a high-speed charge-coupled device (CCD) camera that has an on-board signal processor.
  • This on-board processor is capable of rapid processing of the digital information contained in the images of the sample tubes or sample wells.
  • CCD charge-coupled device
  • This on-board processor is capable of rapid processing of the digital information contained in the images of the sample tubes or sample wells.
  • two images are generated for each location of the well that is being analyzed. These two images differ only in that each is generated under different incident light polarization. Differences in these images due to differential rotation of the polarized light indicates the presence of crystals.
  • the vision system determines the number of crystals in the well, the exact spatial location of the crystals within the well (e.g., X and Y coordinates) and the size of each crystal.
  • This size information directly corresponds to crystal habit.
  • the use of on-line machine vision to determine both the absence/presence of crystals as well as detailed spatial and mo ⁇ hological information has significant advantages. Firstly, this analysis provides a "filtering" means to reduce the number of samples that will ultimately undergo in-depth analysis. Secondly, the spatial information gathered on the locations of crystals is critical to the efficiency in which the in-depth analyses can be performed. This information allows for the specific analysis of individual crystals that are two to four orders of magnitude smaller than the wells that they are contained in. Those wells (reservoirs or sites in the array) identified to contain crystalline or other specific solids can then be further analyzed.
  • Crystallinity can be assessed automatically using plate readers with polarized filter apparatus to measure the total light to determine crystal birefringence. Plate readers are commercially available. It is also possible to monitor turbidity or birefringence dynamically throughout the crystal forming process. Precipitation, which is indicative of crystal formation, is monitored by optical density, which can be visually or spectrophotometrically determined by turbidity. Crystallinity is determined by birefringence which distinguishes crystals from amo ⁇ hous material; crystals turn polarized light, while amo ⁇ hous materials absorb the light.
  • XRPD x-ray Powder Diffraction
  • DSC differential scanning calorimetry
  • TG Thermographic Gravimetric
  • the x-ray crystallography technique whether performed using single crystals or powdered solids, concerns structural analysis and is well suited for the characterization of polymo ⁇ hs and solvates as well as distinguishing amo ⁇ hous from crystalline solids. In the most favorable cases, it can lead to a complete determination of the structure of the solid and the determination of the packing relationship between individual molecules in the solid.
  • Single crystal x-ray diffraction is the preferred analytical technique to characterize crystals generated according to the arrays and methods of the invention. The determination of the crystal structure requires the determination of the unit-cell dimensions and the intensities of a large fraction of the diffracted beams from the crystal.
  • the first step is selection of a suitable crystal. Crystals should be examined under a microscope and separated into groups according to external mo ⁇ hology or crystal habit.
  • each crystal of a completely different external mo ⁇ hology should be examined. Once the crystals have been separated according to shape, the best crystal of the first group should be mounted on a goniometer head with an adhesive such as glue.
  • the unit cell dimension are then determined by photographing the mounted crystal on a precession camera.
  • the unit cell parameters are determined from the precession photograph by measuring the distance between the rows and columns of spots and the angle between a given row and column. This is done for three different orientations of the crystal, thus allowing determination of the unit cell dimensions.
  • the intensities of the diffracted radiation are most conveniently measured using an automated diffractometer that is a computer-controlled device that automatically records the intensities and background intensities of the diffracted beams on a magnetic tape.
  • the diffracted beam is intercepted by a detector, and the intensity is recorded electronically.
  • the diffraction data are then converted to electron density maps using standard techniques, for example, the DENZP program package (Otwinowski, et al, Methods in
  • X-ray Powder Diffraction can also be used.
  • the method that is usually used is called the Debye-Scherrer method (Shoemaker and Garland, 1962).
  • the specimen is mounted on a fiber and placed in the Debye-Scherrer powder camera.
  • This camera consists of an incident-beam collimator, a beam stop, and a circular plate against which the film is placed.
  • the specimen is rotated in the beam. Because the crystallites are randomly oriented, at any given Bragg angle, a few particles are in diffracting position and will produce a powder line whose intensity is related to the electron density in that set of planes.
  • This method along with precession photography, can be used to determine whether crystals formed under different conditions are polymo ⁇ hs or merely differ in crystal habit.
  • To measure a powder pattern of a crystal or crystals on a Debye-Scherrer camera one grinds the sample to a uniform size (200-300 mesh). The sample is then placed in a 0.1- to 0.5- mm-diameter glass capillary tube made of lead-free glass. Commercially made capillary tubes with flared ends are available for this pu ⁇ ose. The capillary tube is placed on a brass pin and inserted into the pin-holder in a cylindrical Debye-Scherrer powder camera.
  • the capillary tube is aligned so that the powdered sample remains in the x-ray beam for a 360° rotation.
  • Film is then placed in the camera, and the sample is exposed to CuK ⁇ x-rays.
  • the film is then developed and the pattern is compared to the pattern from other crystals of the same substance. If the patterns are identical the crystals have the same internal structure. If the patterns are different, then the crystals have a different internal structure and are polymo ⁇ hs.
  • Second Harmonic Generation Symmetry lowering in host-additive systems (crystals inco ⁇ orating guest molecules, e.g., solvates), such as a loss of inversion, glide, or twofold screw symmetry, which would introduce polarity into the crystal, can be probed by non-linear optical effects, such as second harmonic generation, which is active in a noncentrosymmetric crystalline forms.
  • second harmonic generation Second Harmonic Generation
  • This method of analysis involves observation of crystals and physical-state changes of crystals under a microscope (Kuhuert-Brandstatter, 1971). Crystals are usually placed on a microscope slide and covered with a cover slip. However, sometimes a steel ring with input and output tubes is used to control the atmosphere.
  • the microscope slide is often placed on a "hot stage," a commercially available device for heating crystals while allowing observation with a microscope. The heating rate of crystals on a hot stage is usually constant and controlled with the help of a temperature programmer. Crystals are often photographed during heating. Photography is helpful because for solid-state changes taking weeks to complete it is sometimes difficult to remember the appearance of a crystal during the entire change.
  • Thermal analysis generally refers to any method involving heating the sample and measuring the change in some physical property.
  • the most important thermal methods for the study of solid-state chemistry are thermogravimetric analysis (TGA) and differential thermal analysis (DTA).
  • TGA thermogravimetric analysis
  • DTA differential thermal analysis
  • Thermogravimetric analysis involves measuring the change in the mass of the sample as the temperature is changed.
  • Differential thermal analysis involves measuring the difference between the temperature of the sample and a reference compound as the temperature is changed, and provides information on the enthalpy change of various solid-state processes.
  • TGA Thermogravimetric Analysis
  • the atmosphere can have a dramatic effect on the TGA curve.
  • an atmosphere containing the product gas can increase T or stop the change completely.
  • the atmosphere can change the course of the change, particularly if the atmospheric gas reacts with either the products or the reactant.
  • the crystal size of the sample has a predictable effect on the TGA curve. The smaller the crystal size, the faster the physical change and the lower the value of T ⁇ . This is because the small crystals have relatively large surface areas, and more rapid escape of the produce gas is allowed. Obviously, the nature of the change effects T ⁇ .
  • the T x is lower for the more facile physical changes.
  • the extent of compression of the sample will affect the j .
  • thermogravimetric analysis has been used extensively to study the desolvation of crystal solvates.
  • DTA Differential Thermal Analysis
  • T s the temperature of the sample
  • T v the temperature of a reference compound
  • the endotherms represent processes in which heat is absorbed, such as phase transitions and melting.
  • the exotherms represent processes such as chemical reactions where heat is evolved.
  • the area under a peak is proportional to the heat change involved.
  • this method with proper calibration can be used to determine the heats (AH) of the various processes, the temperatures of processes such as melting, T m , can be used as an accurate measure of the melting point.
  • An increased heating rate also usually causes the endotherms and exotherms to become sha ⁇ er.
  • the atmosphere of the sample affects the DTA curve in much the same way it affects the TGA curve. If the atmosphere is one of the reaction products, then increases in its partial pressure would slow down the reaction.
  • the shape of the sample holder and the thermocouple locations can also affect the DTA trace. Thus, it is a good idea to only compare data measured under nearly identical conditions.
  • the crystal size and packing of the sample has an important influence on all reactions of the type solid ⁇ solid + gas. In such reactions, increased crystal size (thus decreased surface area) usually decreases the rate of the reaction and increases the transition temperature.
  • DTA differential scanning calorimetry
  • Differential Scanning Calorimetry refers to a method very similar to DTA in which the ⁇ Hof the reactions and phase transformations can be accurately measured.
  • a DSC trace looks very similar to a DTA trace, and in a DSC trace the area under the curve is directly proportional to the enthalpy change.
  • this method can be used to determine the enthalpies of various processes (Curtin et al, 1969).
  • Electron microscopy is a powerful tool for studying the surface properties of crystals. High-resolution election microscopy can be used to visualize lattice fringes in inorganic compounds, but its usefulness for visualization of lattice fringes in organic compounds is so far unproven. Nevertheless, electron micrographs of organic crystals allow the examination of the crystal surface during physical or chemical change. Electron microscopy is particularly useful for studying the affects of structural imperfections and dislocations on solid-state organic physical or chemical changes. For example, the surface photooxidation of anthracene is obvious from electron micrographs taken at a magnification of 10,000 (Thomas, 1974). Even more interesting is the use of electron microscopy, sometimes in conjunction with optical microscopy, to study the effects of dislocations and various kinds of defects on the nucleation of product phase during a solid state physical change.
  • Electron microscopy is also quite useful for the studies of the effect of crystal size on desolvation physical changes. Electron micrographs have significantly more depth of field than optical micrographs, so that the average crystal size can be more easily determined using them.
  • Fragmentation of the solid materials that formed from the arrays may also be achieved by subjecting stones and other solid materials to laser-generated shock waves.
  • the shock waves produced by lasers generally allow safe fragmentation of urinary calculi compared to the laser-based thermal fragmentation of stones.
  • laser-based fragmentation method requires that the shock wave energy exceed the stone's tensile strength.
  • H.D. Fair and I. Fensel used a laser induced shock wave in 1968 instead of relying on laser thermal effect to fragment stones using a Q-switched Nd-YAG laser.
  • Laser sources that provide short pulses generally tend to generate significantly less thermal effect than continuous wave lasers. The reduced thermal effect leads to less tissue damage.
  • a holmium-YAG laser having a wavelength at 2100 nm (near infrared) has been used to fragment stones successfully.
  • the fragmentation is based on the energy abso ⁇ tion and water vaporization at the stone's surface and its pores.
  • the color and composition of the stones have been found to be irrelevant.
  • the first commercially produced lithotriptor, HM3, was introduced in 1984.
  • most non-passable upper urinary tract stones are treated with extraco ⁇ oreal shock wave lithotripsy.
  • Extraco ⁇ oreal Shock Wave lithotripsy devices There are now about 30 different Extraco ⁇ oreal Shock Wave lithotripsy devices available, and electrohydraulic energy source is one of the most widely-used sources.
  • Raman and Infrared spectroscopy are useful methods for analysis of solids, one advantage being that it can be performed without sample dissolution.
  • the infrared and near infrared spectrum are extremely sensitive to structure and conformation. The method involves grinding the sample and suspending it in Nujor or grinding the sample with KBr and pressing this mixture into a disc. This preparation is then placed in the near infrared or infrared sample beam and the spectrum is recorded.
  • Raman and Infrared spectroscopy are also useful in the investigation of polymo ⁇ hs in the solid state.
  • polymo ⁇ hs A and B of tolbutamide give different infrared spectra (Simmons et al, 1972). It is clear that there are significant differences between the spectra of the polymo ⁇ hs.
  • Ultraviolet spectroscopy is very useful for studying the rates of solid-state physical changes. Such studies require that the amount of reactant or product be measured quantitatively.
  • Pendergrass et al. (1974) developed an ultraviolet method for the analysis of the solid-state thermal physical change of azotribenzoylmethane. In this reaction, the yellow (HI) thermally rearranges to the red (H2) and white (H3) forms in the solid state. All three compounds (HI, H2, and H3) have different chromophores, so that this reaction is amenable to analysis by ultraviolet spectroscopy.
  • Pendergrass developed a matrix-algebra method for analyzing multi component mixtures by ultraviolet spectroscopy and used it to analyze the rate of the solid-state reaction under various conditions.
  • NMR Nuclear Magnetic Resonance
  • the ratio of the areas of the various peaks in proton NMR spectroscopy is equal to the ratio of protons responsible for these peaks.
  • the ratios of areas of peaks from each component are proportional both to the number of protons responsible for the peak and to the amount of the component.
  • Polarography is a special type of voltammetry that uses a dropping mercury electrode. In this experiment an electrochemical reaction is allowed to proceed at a given potential at the electrode and the current flow is measured. The current flow is proportional to the amount of species present. This proportionality is reflected in the well-known Ilkovic equation. Since different compounds undergo reactions at different potentials, polarography, at least in favorable cases, allows the quantitative analysis of one species in the presence of others. However, the "resolution" of polarography is significantly less than other methods such as ultraviolet or NMR spectroscopy. This is because members of one functional class of compounds (i.e., the substituted quinones) undergo electrochemical reaction at potentials close enough that significant overlap between their polarograms occurs. Polarography is sensitive to concentrations down to 10 "5 to 10 "6 M, depending on the functional group undergoing electrochemical reaction.
  • the polarographic experiment must be performed in the absence of dissolved oxygen. This is because oxygen reduction will produce a wave that obscures the reductio of most materials of interest. With water solutions, 5 min of nitrogen bubbling is usually sufficient to remove dissolved oxygen; however, organic solvents often require longer bubbling.
  • Gas chromatography is sometimes used to study the rates and/or course of a solid state reaction.
  • the method involved both dissolving and heating the sample it has inherent drawbacks. Obviously it cannot be used to study solid-state thermal reactions, since the reaction would occur during analysis in the gas chromatography.
  • Gas chromatography is well suited for studying thermally stable materials and has found use in the study of solid-state photochemical reactions as well as desolvations and solid-state hydrolysis reactions.
  • Gas chromatography is rapid, with a typical analysis requiring 5-30 min, and is sensitive. The sensitivity can be greatly enhanced by using a mass spectrometer as a detector.
  • Step 1 A suitable stationary phase (column) is selected.
  • Step 2. The optimum column temperature, flow rate, and column length are selected.
  • Step 3. The best detector is chosen.
  • Step 4. A number of known samples are analyzed, a calibration curve is constructed, and the unknowns are analyzed.
  • High-pressure Liquid Chromato raphy High-pressure liquid chromatography is probably the most widely used analytical method in the pharmaceutical industry. However, because it is a relatively new method (1965-1970), only a few minutes of its use for the study of solid-state reactions are available.
  • a high-pressure liquid chromatography resembles a gas chromatography in that it has an injector, a column, and a detector.
  • high- pressure liquid chromatography it is not necessary to heat the column or sample, making this technique useful for the analysis of heat sensitive materials.
  • column materials ranging from silica to the so-called reversed-phase columns (which are effectively nonpolar columns).
  • detectors are available.
  • the variable-wavelength ultraviolet detector is particularly useful for pharmaceuticals and for studying the solid-state reactions of drugs, since most drugs and their reaction products absorb in the ultraviolet range.
  • extremely sensitive fluorescence and electrochemical detectors are also available.
  • Step 1 Selection of column and detector - these selections are usually based on the physical properties of the reactant and the product.
  • Step 2 Optimization of flow rate and column length to obtain the best separation.
  • Step 3 Analysis of known mixtures of reactant and product and construction of a calibration curve.
  • Thin-layer chromatography (TLC) provides a very simple and efficient method of separation. Only minimal equipment is required for TLC, and very good separations can often be achieved. In general, it is difficult to quantitate TLC, so it is usually used as a method for separation of compounds.
  • Step 1 The adsorbent (stationery phase) is selected and plates either purchased or prepared. Usually silica gel or alumina are used.
  • Step 2 The sample and controls, such as unreacted starting material, are spotted near the bottom of the plate and developed in several solvents until the best separation is discovered. This procedure then gives the researcher a good idea of the number of products formed. Based on these preliminary studies, an efficient preparative separation of the products and reactant can often be designed and carried out. 4.3 Conditions, Compounds, or Compositions That Prevent or Inhibit
  • the invention is useful to discover or optimize conditions, compounds, or compositions that prevent or inhibit crystallization, precipitation, formation, modification, or deposition of disease-causing substances.
  • Possible changes include conformational changes, changes in habit for crystals or of a propensity to aggregate or polymerize for macromolecular aggregates, hi this embodiment, an array is prepared comprising samples having the appropriate medium and having either a dissolved disease- causing substance or having the components necessary — in dissolved or undissolved form — to induce a disease-causing substance.
  • the contents of one or more of the samples is prepared to mimic the in-vivo conditions suitable for forming a disease-causing substance.
  • various components in varying concentrations are added to selected samples and the samples are processed. If desired, particular samples can be processed under various conditions.
  • one or more of the samples differs from one or more other samples by:
  • samples can have one or more of the following components at various concentrations: compounds and compositions that prevent or inhibit precipitation, formation, crystallization, or nucleation; compositions and compounds that promote dissolution, etching, destruction, or breakup of inorganic and organic solids; nucleation promoters; compositions or compounds that affect crystal habit; nutrients; pharmaceuticals; hormones; steroids; proteins and peptides; chelating agents; anti-dental-calculus and anti- dental-plaque agents; excipients; organic solvents; salts; acids; bases; gases; or stabilizers.
  • one or more negative controls contains only the medium and components necessary to mimic the in-vivo conditions suitable to form a disease-causing substance and that does generate the disease-causing substance, thus to guaranteeing the integrity of the experiment.
  • the samples can be analyzed to identify those samples having a disease-causing substance and those that do not.
  • the samples that do not have disease- causing substances are predicative of conditions, compounds, or compositions that prevent or inhibit crystallization, precipitation, formation, or deposition of disease-causing substances.
  • the positive sample can be further analyzed to determine the disease-causing substance's structural, physical, pharmacological, or chemical properties.
  • Structural properties include whether the solid is crystalline or amo ⁇ hous, and if crystalline, the polymo ⁇ hic form and a description of the crystal habit.
  • the disease-causing substance's composition can be analyzed to determine whether it is a hydrate, solvate, or a salt or whether it is mineralized. Also, the surface-to-volume ratio and the degree of particle agglomeration can be determined. Since a high surface-to- volume ratio of particles improves their solubility rate and ease of bodily elimination, in certain contexts, disease- causing substances having a high surface-to-volume are indicative of compositions or conditions that are potentially exploitable.
  • Other physical properties that can be measured include melting point, solubility, strength, hardness, compressibility, compactability, and resistance to energy forms, such as ultrasound, shock waves, and laser energy.
  • the experiment can reveal conditions, compounds, or compositions that form disease-causing substances more favorable than would otherwise be formed (e.g., those of the negative control or tliose formed in vivo).
  • compounds, compositions, or conditions that induce formation of disease-causing substances that are easily destroyed or fragmented by ultrasound or shock waves are therapeutically exploitable.
  • the invention is useful to discover or optimize conditions, compounds, and compositions that promote dissolution, destruction, or breakup of inorganic and organic solids, particularly disease-causing substances.
  • an array is prepared comprising samples having the appropriate medium and having a disease-causing substance, preferably, in solid form. Then, if desired, various components in varying concentrations are added to selected samples and the samples are processed. If desired, particular samples can be processed under various conditions. Preferably, one or more of the samples differs from one or more other samples by:
  • samples can have one or more of the following components at various concentrations: compounds and compositions that prevent or inhibit precipitation, formation, crystallization, or nucleation; compositions and compounds that promote dissolution, etching, destruction, or breakup of inorganic and organic solids; nucleation promoters; compositions or compounds that affect crystal habit; nutrients; pharmaceuticals; hormones; steroids; proteins and peptides; chelating agents; anti-dental-calculus and anti- dental-plaque agents; excipients; organic solvents; salts; acids; bases; gases; or stabilizers.
  • one or more negative controls contains only the medium and the disease- causing substance.
  • the samples can be analyzed to identify positive samples, i.e., samples wherein the disease-causing substance changed in physical state, such as by partially or fully dissolving, by fragmenting, by increasing surface-to- volume ratio, by polymo ⁇ hic shift, by change in crystal habit, or has otherwise been rendered physically, structurally, or chemically more favorable.
  • positive samples i.e., samples wherein the disease-causing substance changed in physical state, such as by partially or fully dissolving, by fragmenting, by increasing surface-to- volume ratio, by polymo ⁇ hic shift, by change in crystal habit, or has otherwise been rendered physically, structurally, or chemically more favorable.
  • Structural properties related to solids include whether the solid is crystalline or amo ⁇ hous, and if crystalline, the polymo ⁇ hic form and a description of the crystal habit.
  • the disease-causing substance's composition can be analyzed to determine whether it is a hydrate, solvate, or a salt or whether it is mineralized. Also, the surface-to-volume ratio and the degree of particle agglomeration can be determined. Since a high surface-to- volume ratio of particles improves their solubility rate and ease of bodily elimination, in certain contexts, disease-causing substances having a high surface-to-volume are indicative of compositions or conditions that are potentially exploitable. Other physical properties that can be measured include melting point, solubility, strength, hardness, compressibility, compactability, and resistance to energy forms, such as ultrasound, shock waves, and laser energy. Thus, this experiment can reveal conditions, compounds, or compositions that convert disease-causing substances to more favorable forms.
  • the final step of the methods discussed herein is to select and further analyze samples with the most desirable properties, for example, selection and clinical exploitation of samples wherein crystallization, precipitation, formation, or deposition of disease-causing substances was prevented or inhibited, relative to a negative control; selection and clinical exploitation of samples where dissolution, destruction, or breakup of disease-causing substances was promoted, relative to a negative control; or selection and clinical exploitation of samples where formation of a desirable substance was promoted, relative to a negative control. From such samples, clinically-relevant conditions, compounds, or compositions can be identified and exploited to treat (e.g., reverse) or prevent the disease itself, the cause of the disease, or the symptoms of the disease.
  • Clinically relevant compounds and compositions can be assayed, for use as drugs to treat or prevent the diseases of physical-state transition mentioned in section 2.2 above.
  • the clinically relevant compounds and compositions can be assayed for effectiveness, potency, toxicity, abso ⁇ tion, and metabolism using in-vitro and in-vivo tests and experiments well known to those skilled in the pharmaceutical arts.
  • Sickle Cell Disease is caused by a single nucleotide substitution resulting in a substitution of the amino acid Glu for Val on the sixth position of the beta-globin polypeptide chain.
  • This seemingly minor change in amino acid composition of the globin protein causes a profound change in the solubility of deoxygenated hemoglobin containing either one or two such abnormal beta-globin molecules.
  • HbS Deoxygenated sickle cell hemoglobin
  • erythrocytes i.e., deformation of otherwise substantially rigid red blood cells that, in turn, causes occlusion of the micro vasculature.
  • This polymerization depends on the rate of nucleation for formation of deoxygenated hemoglobin polymers that are pathological aggregations of HbS. The rate of nucleation leading to such polymerization is lower at a reduced temperature, a property exploited in several therapeutic strategies described next.
  • a preparation of deoxygenated HbS is maintained at a low temperature while being aliquoted and mixed with test compounds of interest.
  • the aliquots exhibiting delayed polymerization indicate desired activity possessing compounds. It is noteworthy that even a small delay in nucleation is clinically significant in alleviating the disease phenotype.
  • the compounds of interest have already been subjected to clinical trials, or are otherwise known compounds, then they can be rapidly subjected to further analysis to better define the new use in treating sickle cell disease condition.
  • the invention is not limited to finding uses for known compounds and formulations, but includes discovery of novel compounds and formulations. Similar screening is possible in modulating other polymerization based processes such as aggregation of fibrin in the course of blood clot formation. Modulating, e.g., preventing the formation of blood clots is desirable in many clinical settings to avoid the risk of strokes while, promoting the formation of blood clots is desirable in diseases such as hemophilia.
  • Another example of preventing polymerization of a substance of interest for treating a disease is provided by malaria.
  • the well known anti-malarial chloroquine exerts its antimalarial activity through interaction with hematin in the lysosomal digestive vacuole of the malaria parasite.
  • the invention encompasses high-throughput assays for identifying compounds, especially small molecules that can inhibit hemoglobin polymerization and/or be useful for treating sickle cell disease, as well as alternative embodiments being useful for discovering substances and formulations targeting dissolution of hemozoin, or preventing hemazoin formation, or micro-tubule polymerization or depolymerization among many possible applications.
  • Substances promoting dissolution of hemazoin provide a strategy to generate improved compounds and formulations that do not depend on continued hemoglobin degradation by the malarial parasite for generating toxic hematin and instead, or in addition, generate toxic hematin from already formed hemazoin.
  • Such compounds and formulations may provide better treatment options with higher efficacy in combating malaria, particularly in already infected individuals.
  • Such a screen is possible by detecting dissolution of hemazoin to yield hematin in the presence of a test compound or formulation over time.
  • the ready availability of small animal models of malaria enables rapid and routine further testing.
  • the described exemplary method and system identifies compounds that inhibit formation of Uric acid crystal deposits that are a characteristic of gout.
  • the described method and system are readily applicable to screen for compounds to treat calcium containing deposits of pseudogout. Both of these disease conditions are described in greater detail in ⁇ 2.2.1 and 2.2.4.
  • the following illustrative description is directed to uric acid crystals of gout.
  • the method and system include generating an array of vessels containing test compounds such that each vessel contains a test compound aliquot, mixing the test compounds with urate saturated human plasma, increasing the supersaturation of urate in the mixture of human plasma and test compounds by decreasing the temperature, preferably gradually, and identifying test compounds in whose presence crystals fail to form.
  • These vessels may be in the form of wells in a multi- well plate, drops on a suitable surface, or other suitable containers.
  • Urate saturated biological fluid (“USF”), wherein example biological fluids include human plasma, joint fluid, and other fluids in various compartments, can be prepared, for instance, by dissolving crystalline monosodium urate, e.g., obtained from Sigma Chemicals of St.
  • USF is allowed to achieve equilibrium saturation with urate although it is possible to practice the invention without always ensuring such saturation. Undissolved Urate is removed by centrifuging to obtain USF as the supernatant. USF is dispensed into vessels suitable for monitoring for crystal precipitation and mixed with the test compounds placed in the vessels.
  • the test compounds may advantageously be provided as an aqueous preparation.
  • the vessels are sealed or otherwise treated to reduce evaporative losses.
  • the vessels are maintained to reduce the likelihood of precipitation of crystals during the USF preparation, aliquoting and mixing steps, e.g., by preheating the receiving vessels.
  • a reduction in temperature preferably gradual, then induces urate crystallization.
  • the vessels are monitored, e.g., optically, for the appearance of crystals or lack thereof.
  • the brightly birefringent urate crystals are susceptible to various monitoring methods including polarimeters and turbidity.
  • Vessels that fail to form crystalline precipitates or are delayed in forming of such precipitates are suitable for further screening since they are more likely to correspond to test compounds suitable for inhibiting formation of uric acid crystals.
  • nucleation is a stochastic and kinetic event
  • many identical compositions are tested to achieve a meaningful statistical estimate of changes therein.
  • the number of replicates reflect the underlying probability distribution to ensure that observed nucleation rate is reliable with a probability of preferably 66%, more preferably 99% and even more preferably 95%.
  • each set of test compounds are tested in at least four vessels, more preferably in twenty or more vessels and even more preferably in ten to twenty vessels.
  • test compounds likely to be useful as inhibitors of uric acid crystal formation, they may be further tested in vivo.
  • the availability of the urate oxidase deficient mouse described by Wu et al. in the Proceedings of the National Academy of Sciences USA in volume 91 at pages 742-746, said reference inco ⁇ orated herein in its entirety by reference, makes possible further evaluation of selected test compounds.
  • This evaluation can include estimating safety, preliminary dosage and other parameters relating to each test compound.
  • the urate oxidase deficient mouse exhibits enhanced mortality in the first four weeks of life (by 65%) and also shows signs of kidney damage in affected mice. Therefore, it is sensitive and rapid small animal model for evaluating compounds of interest in inhibiting uric acid crystal formation.
  • the development of additional animal species and strains that lack urate oxidase would further extend the range of available animal model systems.
  • test compounds could be used in humans.
  • the test compounds are advantageously chosen from the set of compounds that are known to be safe for administration to humans, e.g., such as those having passed Phase I clinical trials.
  • these compounds maybe advantageously be tested for treating gout in clinical trials (Phase II or Phase HI) to discover new uses for known compounds in an economical and safe manner or administered for such treatment.
  • Other trials evaluating clinical efficacy such as pediatric trial, gender sensitive testing and testing directed to use of compounds in particular ethnic or geographically defined groups are also possible.
  • novel compounds for the treatment of uric acid crystal deposition are also identified by the described method and system a suitable choice of test compounds.
  • libraries can be screened to identify useful compounds.
  • the invention encompasses high-throughput assays for identifying compounds, especially small molecules that can inhibit formation of uric acid crystals.
  • Such compounds may be known compounds or novel compounds and may act to prevent or alleviate one or more disease symptoms.
  • a system and method similar to that described in ⁇ 4.5.1.2 are useful for identifying such compounds, hi a possible variant, vessels containing USP and test compounds are incubated at increasing temperatures to achieve subsaturation with respect to uric acid.
  • urate crystals prior to increasing the temperature, urate crystals are allowed to precipitate by lowering the temperature followed by mixing with the test compounds. Agitation of the subsaturated solution allows for an assessment of the rate of dissolution of crystals. Vessels corresponding to fast dissolving crystals are identified to further test the corresponding test compounds for modification of uric acid crystals including their habit, and activity, and safety in vivo.
  • the urate oxidase mouse provides a useful model for evaluating safety, efficacy in vivo and dosage.
  • Test compounds so identified have utility as medicines, for instance as administered to patients receiving uric acid lowering therapies.
  • the invention encompasses high-throughput assays for identifying compounds, especially small molecules that can promote the dissolution of deposited uric acid crystals in the course of treating gout.
  • Such compounds may be known compounds or novel compounds and may act to prevent or alleviate one or more disease symptoms.
  • the invention also encompasses the use of such compounds identified in the assays to treat diseases.
  • the invention encompasses high-throughput assays for identifying compounds, especially small molecules that can inhibit the formation of or promote the dissolution of Calcium containing crystals and other types of crystals that otherwise result in a disease state.
  • compounds may be known compounds or novel compounds and may act to prevent or alleviate one or more disease symptoms.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des réseaux comprenant des centaines, des milliers, jusqu'à des centaines de milliers d'échantillons, ainsi que des procédés de criblage de ces derniers. Ces procédés sont utiles pour optimiser, sélectionner et découvrir des composés, des compositions ou des conditions qui préviennent, inhibent, induisent, modifient ou inversent des transitions d'état physique, notamment des transitions d'état physique in vivo liées à des processus pathogènes. Ces composés, compositions ou conditions peuvent être utilisés pour traiter (p. ex. inverser) ou prévenir la maladie elle-même, la cause de la maladie ou les symptomes de la maladie.
PCT/US2001/044818 2000-01-07 2001-11-28 Identification rapide de conditions, de composes ou de compositions qui inhibent, previennent, induisent, modifient ou inversent des transitions d'etat physique WO2002044730A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2002217953A AU2002217953A1 (en) 2000-11-28 2001-11-28 Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US10/103,983 US20050118637A9 (en) 2000-01-07 2002-03-22 Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US10/142,812 US20050089923A9 (en) 2000-01-07 2002-05-10 Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US10/235,553 US20050095696A9 (en) 2000-01-07 2002-09-06 Apparatus and method for high-throughput preparation and characterization of compositions
US10/235,922 US6977723B2 (en) 2000-01-07 2002-09-06 Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US10/235,922 US20040252299A9 (en) 2000-01-07 2002-09-06 Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
US11/051,517 US7061605B2 (en) 2000-01-07 2005-01-31 Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25362900P 2000-11-28 2000-11-28
US60/253,629 2000-11-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/994,585 Continuation-In-Part US7108970B2 (en) 2000-01-07 2001-11-27 Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/103,983 Continuation-In-Part US20050118637A9 (en) 2000-01-07 2002-03-22 Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds
US10/142,812 Continuation-In-Part US20050089923A9 (en) 2000-01-07 2002-05-10 Method and system for planning, performing, and assessing high-throughput screening of multicomponent chemical compositions and solid forms of compounds

Publications (1)

Publication Number Publication Date
WO2002044730A1 true WO2002044730A1 (fr) 2002-06-06

Family

ID=22961045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044818 WO2002044730A1 (fr) 2000-01-07 2001-11-28 Identification rapide de conditions, de composes ou de compositions qui inhibent, previennent, induisent, modifient ou inversent des transitions d'etat physique

Country Status (2)

Country Link
AU (1) AU2002217953A1 (fr)
WO (1) WO2002044730A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740930A2 (fr) * 2004-03-12 2007-01-10 S.S.C.I., Inc Criblage pour des formes solides par la cristallisation par ultrasons et la co-cristallisation utilisant des ultrasons
WO2009102453A2 (fr) * 2008-02-11 2009-08-20 The General Hospital Corporation Système et procédé pour évaluer quantitativement le comportement migratoire de particules biologiques
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
US7771938B2 (en) 2004-09-20 2010-08-10 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
US8790891B2 (en) 2009-03-19 2014-07-29 The General Hospital Corporation Microfluidic cell motility assay
US10670583B2 (en) 2013-09-20 2020-06-02 The General Hospital Corporation Cell chemotaxis assays
US11130132B2 (en) 2016-05-06 2021-09-28 The General Hospital Corporation Microfluidic neutrophil assays and systems for disease detection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331440B1 (en) * 1995-12-12 2001-12-18 Karolinska Innovations Ab Peptide binding the KLVFF-sequence of amyloid-β

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331440B1 (en) * 1995-12-12 2001-12-18 Karolinska Innovations Ab Peptide binding the KLVFF-sequence of amyloid-β

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GADAMASETTI K.G.: "Process chemistry in the pharmaceutical industry", 1999, MARCEL DEKKER, INC., NY, NY *
REIXACH ET AL.: "Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library", JOURNAL STRUCTURAL BIOLOGY, vol. 130, 2000, pages 247 - 258, XP002908684 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740930A2 (fr) * 2004-03-12 2007-01-10 S.S.C.I., Inc Criblage pour des formes solides par la cristallisation par ultrasons et la co-cristallisation utilisant des ultrasons
EP1740930A4 (fr) * 2004-03-12 2010-09-15 Aptuit Kansas City Llc Criblage pour des formes solides par la cristallisation par ultrasons et la co-cristallisation utilisant des ultrasons
US7771938B2 (en) 2004-09-20 2010-08-10 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
WO2009102453A2 (fr) * 2008-02-11 2009-08-20 The General Hospital Corporation Système et procédé pour évaluer quantitativement le comportement migratoire de particules biologiques
WO2009102453A3 (fr) * 2008-02-11 2009-11-19 The General Hospital Corporation Système et procédé pour évaluer quantitativement le comportement migratoire de particules biologiques
US8921122B2 (en) 2008-02-11 2014-12-30 The General Hospital Corporation System and method for quantitative assessment of biological migration behavior
US8790891B2 (en) 2009-03-19 2014-07-29 The General Hospital Corporation Microfluidic cell motility assay
US10670583B2 (en) 2013-09-20 2020-06-02 The General Hospital Corporation Cell chemotaxis assays
US11460465B2 (en) 2013-09-20 2022-10-04 The General Hospital Corporation Cell chemotaxis assays
US11130132B2 (en) 2016-05-06 2021-09-28 The General Hospital Corporation Microfluidic neutrophil assays and systems for disease detection

Also Published As

Publication number Publication date
AU2002217953A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
US7108970B2 (en) Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
CN103781770B (zh) 转甲状腺素蛋白解离抑制剂的固体形式
Ouyang et al. Effects of carboxylic acids on the crystal growth of calcium oxalate nanoparticles in lecithin− water liposome systems
O'Sullivan et al. In situ monitoring of polymorphic transitions
Khan et al. The precipitation behavior of poorly water-soluble drugs with an emphasis on the digestion of lipid based formulations
CZ20022332A3 (cs) Sestava vzorků
EP1558931B1 (fr) Analyse des stabilite et solubilite pharmaceutiques
JP4008816B2 (ja) 浮揚させた小滴で分子の核生成傾向をスクリーニングするためのシステム及び方法
WO2002044730A1 (fr) Identification rapide de conditions, de composes ou de compositions qui inhibent, previennent, induisent, modifient ou inversent des transitions d'etat physique
DE60037883T2 (de) Einarbeitung und anwendung von biomolekularen wechselwirkungen innerhalb einem trägermittel
Steele et al. Preformulation investigations using small amounts of compound as an aid to candidate drug selection and early development
Lau Preformulation studies
Vertzoni et al. UNGAP best practice for improving solubility data quality of orally administered drugs
US20020132758A1 (en) Method for identifying compounds to treat medical pathologies associated with molecular crystallization
Geng et al. Crystallization of hierarchical ammonium urate: insight into the formation of cetacean renal stones
US20050233461A1 (en) High-throughput methods and systems for screening of compounds to treat/prevent kidney disorders
WO2011036297A2 (fr) Méthode de thérapie et de diagnostic de morbus alzheimer
US20100210027A9 (en) Method for determining effect of preformulation forms on their dissolution rates
Zhao et al. Multivariate Analysis of a Highly Effective Drug Combination Tablet Containing the Antiepileptic Drug Gabapentin to Enhance Pharmaceutical Properties with a Multicomponent Crystal Strategy
Bhatt et al. Development of L-lysine amino acid-based co-crystal of telmisartan using crystal engineering approach to improve solubility, dissolution, and micrometric properties
Halbert Preformulation
Smith The evaluation of microwave drying on the polymorphic characteristics of carbamazepine granules prepared by the wet granulation process.
PUNMALEE EFFECT OF SOLVENT ON CRYSTALLIZATION AND POLYMORPHIC TRANSFORMATION OF L-HISTIDINE
KR20230000978A (ko) 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
Horstman Crystallization of active pharmaceutical ingredients using microfluidic platforms and meniscus-guided coating

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP